<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure - Sweeney, C - 2019 | Cochrane Library</title> <meta content="Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure - Sweeney, C - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013015.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure - Sweeney, C - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013015.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013015.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure" name="citation_title"/> <meta content="Claire Sweeney" name="citation_author"/> <meta content="claire.sweeney@heartbeat-trust.org" name="citation_author_email"/> <meta content="Fiona Ryan" name="citation_author"/> <meta content="The Heartbeat Trust" name="citation_author_institution"/> <meta content="Mark Ledwidge" name="citation_author"/> <meta content="Cristin Ryan" name="citation_author"/> <meta content="Trinity College Dublin" name="citation_author_institution"/> <meta content="Ken McDonald" name="citation_author"/> <meta content="Chris Watson" name="citation_author"/> <meta content="Queen's University Belfast" name="citation_author_institution"/> <meta content="Rebabonye B Pharithi" name="citation_author"/> <meta content="The Heartbeat Trust" name="citation_author_institution"/> <meta content="Joe Gallagher" name="citation_author"/> <meta content="Irish College of General Practitioners" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD013015.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/10/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013015.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013015.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013015.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013015.pub2&amp;doi=10.1002/14651858.CD013015.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="QzbxnhyM";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013015\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013015\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ms","fa","zh_HANS","hr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013015.pub2",title:"Natriuretic peptide\\u2010guided treatment for the prevention of cardiovascular events in patients without heart failure",firstPublishedDate:"Oct 15, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013015.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013015.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013015.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013015.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013015.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013015.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013015.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013015.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013015.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013015.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6388 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013015.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0061"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-sec-0086"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/appendices#CD013015-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/table_n/CD013015StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/table_n/CD013015StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Claire Sweeney</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0003">Fiona Ryan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0004">Mark Ledwidge</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0005">Cristin Ryan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0006">Ken McDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0007">Chris Watson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0008">Rebabonye B Pharithi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information#CD013015-cr-0009">Joe Gallagher</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information/en#CD013015-sec-0108">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 October 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013015.pub2">https://doi.org/10.1002/14651858.CD013015.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013015-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013015-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013015-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013015-abs-0001" lang="en"> <section id="CD013015-sec-0001"> <h3 class="title" id="CD013015-sec-0001">Background</h3> <p>Cardiovascular disease (CVD) is the leading cause of morbidity and mortality globally. Early intervention for those with high cardiovascular risk is crucial in improving patient outcomes. Traditional prevention strategies for CVD have focused on conventional risk factors, such as overweight, dyslipidaemia, diabetes, and hypertension, which may reflect the potential for cardiovascular insult. Natriuretic peptides (NPs), including B‐type natriuretic peptide (BNP) and N‐terminal pro B‐type natriuretic peptide (NT‐proBNP), are well‐established biomarkers for the detection and diagnostic evaluation of heart failure. They are of interest for CVD prevention because they are secreted by the heart as a protective response to cardiovascular stress, strain, and damage. Therefore, measuring NP levels in patients without heart failure may be valuable for risk stratification, to identify those at highest risk of CVD who would benefit most from intensive risk reduction measures. </p> </section> <section id="CD013015-sec-0002"> <h3 class="title" id="CD013015-sec-0002">Objectives</h3> <p>To assess the effects of natriuretic peptide (NP)‐guided treatment for people with cardiovascular risk factors and without heart failure. </p> </section> <section id="CD013015-sec-0003"> <h3 class="title" id="CD013015-sec-0003">Search methods</h3> <p>Searches of the following bibliographic databases were conducted up to 9 July 2019: CENTRAL, MEDLINE, Embase, and Web of Science. Three clinical trial registries were also searched in July 2019. </p> </section> <section id="CD013015-sec-0004"> <h3 class="title" id="CD013015-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials enrolling adults with one or more cardiovascular risk factors and without heart failure, which compared NP‐based screening and subsequent NP‐guided treatment versus standard care in all settings (i.e. community, hospital). </p> </section> <section id="CD013015-sec-0005"> <h3 class="title" id="CD013015-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened titles and abstracts and selected studies for inclusion, extracted data, and evaluated risk of bias. Risk ratios (RRs) were calculated for dichotomous data, and mean differences (MDs) with 95% confidence intervals (CIs) were calculated for continuous data. We contacted trial authors to obtain missing data and to verify crucial study characteristics. Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, two review authors independently assessed the quality of the evidence and GRADE profiler (GRADEPRO) was used to import data from Review Manager to create a 'Summary of findings' table. </p> </section> <section id="CD013015-sec-0006"> <h3 class="title" id="CD013015-sec-0006">Main results</h3> <p>We included two randomised controlled trials (three reports) with 1674 participants, with mean age between 64.1 and 67.8 years. Follow‐up ranged from 2 years to mean 4.3 years. </p> <p>For primary outcome measures, effect estimates from a single study showed uncertainty for the effect of NP‐guided treatment on cardiovascular mortality in patients with cardiovascular risk factors and without heart failure (RR 0.33, 95% CI 0.04 to 3.17; 1 study; 300 participants; low‐quality evidence). Pooled analysis demonstrated that in comparison to standard care, NP‐guided treatment probably reduces the risk of cardiovascular hospitalisation (RR 0.52, 95% CI 0.40 to 0.68; 2 studies; 1674 participants; moderate‐quality evidence). This corresponds to a risk of 163 per 1000 in the control group and 85 (95% CI 65 to 111) per 1000 in the NP‐guided treatment group. </p> <p>When secondary outcome measures were evaluated, evidence from a pooled analysis showed uncertainty for the effect of NP‐guided treatment on all‐cause mortality (RR 0.90, 95% CI 0.60 to 1.35; 2 studies; 1354 participants; low‐quality evidence). Pooled analysis indicates that NP‐guided treatment probably reduces the risk of all‐cause hospitalisation (RR 0.83, 95% CI 0.75 to 0.92; 2 studies; 1354 participants; moderate‐quality evidence). This corresponds to a risk of 601 per 1000 in the control group and 499 (95% CI 457 to 553) per 1000 in the NP‐guided treatment group. The effect estimate from a single study indicates that NP‐guided treatment reduced the risk of ventricular dysfunction (RR 0.61, 95% CI 0.41 to 0.91; 1374 participants; high‐quality evidence). The risk in this study's control group was 87 per 1000, compared with 53 (95% CI 36 to 79) per 1000 with NP‐guided treatment. Results from the same study show that NP‐guided treatment does not affect change in NP level at the end of follow‐up, relative to standard care (MD ‐4.06 pg/mL, 95% CI ‐15.07 to 6.95; 1 study; 1374 participants; moderate‐quality evidence). </p> </section> <section id="CD013015-sec-0007"> <h3 class="title" id="CD013015-sec-0007">Authors' conclusions</h3> <p>This review shows that NP‐guided treatment is likely to reduce ventricular dysfunction and cardiovascular and all‐cause hospitalisation for patients who have cardiovascular risk factors and who do not have heart failure. Effects on mortality and natriuretic peptide levels are less certain. Neither of the included studies were powered to evaluate mortality. Available evidence shows uncertainty regarding the effects of NP‐guided treatment on both cardiovascular mortality and all‐cause mortality; very low event numbers resulted in a high degree of imprecision in these effect estimates. Evidence also shows that NP‐guided treatment may not affect NP level at the end of follow‐up. </p> <p>As both trials included in our review were pragmatic studies, non‐blinding of patients and practices may have biased results towards a finding of equivalence. Further studies with more adequately powered sample sizes and longer duration of follow‐up are required to evaluate the effect of NP‐guided treatment on mortality. As two trials are ongoing, one of which is a large multi‐centre trial, it is hoped that future iterations of this review will benefit from larger sample sizes across a wider geographical area. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013015-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013015-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD013015-abs-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013015-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013015-abs-0010">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013015-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013015-abs-0004" lang="en"> <h3>Natriuretic peptide‐guided treatment for preventing death and cardiovascular events among patients with risk factors for heart disease </h3> <p><b>Review question</b> </p> <p>We wanted to see if natriuretic peptide (NP)‐guided treatment is better than usual care for preventing death and cardiovascular events among patients with risk factors for heart disease but without heart failure. </p> <p><b>Background</b> </p> <p>Cardiovascular diseases (CVDs) are a group of conditions that affect the heart and blood vessels. They are the leading causes of avoidable death worldwide. Risk factors that increase a person's likelihood of developing CVD include diabetes, high blood pressure, high cholesterol, and obesity. Natriuretic peptides (NPs) are hormones produced by the heart that are measured in the blood. They help the body to eliminate fluids, relax the blood vessels, and funnel sodium into the urine. When the heart is damaged, the body releases more NPs to try to ease strain on the heart. By measuring a person's blood NP levels, we can identify those who have established damage to their heart and who are at higher risk of death and cardiovascular events such as heart attack and stroke. We can then use this information to reduce a person's cardiovascular risk by guiding decisions about their cardiovascular care (NP‐guided treatment), such as what medication they should take, what investigations they need, and what adjustments they should make to their lifestyle. </p> <p><b>Study characteristics</b> </p> <p>Evidence in this review is current to July 2019. We included two randomised controlled trials (where participants have an equal chance of being assigned to either treatment) including 1674 adult participants who had one or more risk factors for developing CVD, which compared NP‐guided treatment with standard care. We excluded patients with symptoms of heart failure. The mean age of participants varied between 64.1 and 67.8 years. Patients were followed‐up for between 2 years and a mean of 4.2 years. </p> <p><b>Key results</b> </p> <p>Effects of NP‐guided treatment on death due to CVD or for any other reason remain uncertain as our results were imprecise. Moderate‐quality evidence suggests that NP‐guided treatment probably reduces the number of hospitalisations due to cardiovascular events and due to all causes in patients with cardiovascular risk factors. We would expect that of 1000 patients who received standard care, 163 would be admitted to hospital as the result of a cardiovascular event, compared to between 65 and 111 patients who received NP‐guided treatment. Out of 1000 patients with cardiovascular risk factors who received standard care, 601 would be admitted to hospital for any reason, compared to between 457 and 553 patients who received NP‐guided treatment. </p> <p>High‐quality evidence indicates that NP‐guided treatment reduces the risk of ventricular dysfunction (a condition that often leads to heart failure) compared to standard care. Our results suggest that of 1000 patients with cardiovascular risk factors who received standard care, 87 would develop ventricular dysfunction, compared to between 36 and 79 patients who received NP‐guided treatment. No evidence suggests that NP‐guided treatment affected NP level at completion of the studies. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence ranged from low to high across outcomes. Key reasons for concern about the quality of the evidence included risk of bias, as patients and medical staff caring for patients knew whether they were in the control or intervention group and this may have affected the care they received; some results obtained were imprecise, and it is unclear if the intervention was beneficial or harmful. As we identified only two studies that were suitable for inclusion in this review, the generalisability of the review is limited. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013015-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-sec-0092">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-sec-0154">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013015-sec-0092"></div> <h3 class="title" id="CD013015-sec-0093">Implications for practice</h3> <section id="CD013015-sec-0093"> <p>The evidence presented in this review suggests that natriuretic peptide (NP)‐guided treatment has a beneficial effect on several outcomes in people with cardiovascular risk factors and without heart failure. </p> <p>We found moderate‐quality evidence to show that NP‐guided treatment probably reduces the risk of cardiovascular hospitalisation and all‐cause hospitalisation in patients without heart failure. Low‐quality evidence suggests uncertainty regarding the effects of NP‐guided treatment on cardiovascular mortality and all‐cause mortality. Thus, until new data are published, the evidence is indeterminate for these outcomes. We found high‐quality evidence from a single‐centre trial showing that NP‐guided treatment has a beneficial effect on the risk of developing ventricular dysfunction. </p> <p>Although NP‐guided treatment has been included in guidelines in both the United States and Canada as a recommendation for patients at risk of developing heart failure (<a href="./references#CD013015-bbs2-0032" title="EzekowitzJA , O'MearaE , McDonaldMA , AbramsH , ChanM , DucharmeA , et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology2017;33(11):1342‐433. ">Ezekowitz 2017</a>; <a href="./references#CD013015-bbs2-0100" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , ColvinMM , et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation2017;136:137‐61. ">Yancy 2017</a>), no evidence indicates that it has been adopted into routine clinical practice. Our review consolidates the current evidence base, but uncertainties remain regarding the effects of NP‐guided treatment on mortality and in different populations and subgroups. Furthermore, the evidence presented in our review pertains to NP‐guided treatment delivered within the setting of a specialist cardiology clinic; therefore further research is required to investigate the effectiveness of the intervention when delivered in other practice settings such as primary care. </p> </section> <h3 class="title" id="CD013015-sec-0094">Implications for research</h3> <section id="CD013015-sec-0094"> <p>Currently, NP‐guided treatment is a broad term incorporating a diverse range of interventions, from complex multi‐component interventions incorporating modification of drug therapy, diagnostic and investigational strategies, and educational and lifestyle interventions, to single‐component interventions focusing solely upon modification and optimisation of pharmacological therapy. Thus, there is uncertainty about the optimal approach to delivering NP‐guided treatment for people without heart failure. Further research is required to develop a consensus statement to define the essential components of NP‐guided treatment to allow for research replication and evaluation of efficacy. </p> <p>Exploration of subgroups of patients with different cardiovascular risk factors (e.g. diabetes, obesity) would be useful to investigate whether all people with cardiovascular risk factors derive similar benefit from NP‐guided treatment, or whether efforts should be targeted towards specific subpopulations. Although we were able to conduct subgroup analysis by NP level, a more stratified analysis would help to determine the optimal level for risk stratification and would allow more accurate application of the intervention to those at highest risk. Although evidence from our review suggests that NP‐guided treatment probably does not affect change in NP level at the end of follow‐up, clear consensus on what is considered a clinically significant change in NP level among patients without heart failure is needed. Furthermore, the optimal time points for measurement of NP levels should be detailed to allow for standardised measurements across clinical trials. </p> <p>Our review included two studies conducted within large urban centres in high‐income countries in Europe, with predominantly Caucasian participants. Further multi‐centre studies are required to explore the effects of NP‐guided treatment among persons of different ethnicity and from different healthcare systems and income settings, to ultimately characterise the intervention that is most universally effective. The effectiveness of NP‐guided treatment when delivered through settings other than a specialist cardiology outpatient clinic is unknown, and research examining the effectiveness of the intervention delivered in other settings such as primary care is required. </p> <p>A core outcome set should be compiled through consultation with stakeholders such as patients, clinicians, and policy‐makers, to ensure that the outcomes measured by researchers are reflective of the priorities and perspectives of those with a vested interest in the intervention in question. This set of standardised research outcomes will permit comparison and meta‐analysis of results across studies, thus strengthening the body of evidence. </p> <p>Our review shows uncertainty about the effects of NP‐guided treatment on mortality, and adequately powered studies with longer duration of follow‐up (10 to 15 years) are needed to address the question of whether there is a treatment effect on this outcome. </p> <p>Two ongoing trials may affect our confidence in the estimates of effect and may change current estimates (<a href="./references#CD013015-bbs2-0018" title="DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . NT proBNP ‐ an important decision factor in preventing heart failure. European Journal of Clinical Investigation2015;2:6. DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. European Journal of Heart Failure2015;17:420‐31. DimitriuI , RaileanuM , AndreiC , SinescuC . NTproBNP ‐ an important decision factor in preventing heart failure. Proceedings of the 49th Annual Society Meeting of the European Society for Clinical Investigation. 2015:147‐51. DimitriuI , RaileanuM , CalinC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. Journal of Hypertension2015;33:e461‐2. DimitriuI , VoiculescuD , LacraruA , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in diabetic patients. European Journal of Clinical Investigation2017;47(Suppl 1):100. DimitriuI , VoiculescuD , RaileanuM , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in hypertensive patients. European Journal of Heart Failure2016;18(Suppl 1):249. DimitriuI , VoiculescuD , SinescuC . NTproBNP in patients with hypertension to prevent heart failure. European Journal of Clinical Investigation2016;1:15‐6. DimitriuI , Voiculescu , LacraruA , SinescuC . NT pro BNP ‐ a decision factor in preventing heart failure in diabetic patients. European Journal of Heart Failure2017;9(Suppl 1):408. Dimitriu I. Preventing heart failure using medical intervention guided by NTproBNP. Preventing heart failure using medical intervention guided by NTproBNP. Journal of Economic Computation and Economic Cybernetics Studies and Research2015;1:228‐36. ">Dimitriu 2015</a>; <a href="./references#CD013015-bbs2-0019" title="NCT02817360. NT‐proBNP selected prevention of cardiac events in diabetic patients. clinicaltrials.gov/ct2/show/NCT02817360?term=PONTIAC&amp;rank=2 (first posted 29 June 2016). ">Huelsmann 2016</a>). In particular, <a href="./references#CD013015-bbs2-0019" title="NCT02817360. NT‐proBNP selected prevention of cardiac events in diabetic patients. clinicaltrials.gov/ct2/show/NCT02817360?term=PONTIAC&amp;rank=2 (first posted 29 June 2016). ">Huelsmann 2016</a> may have a significant impact on the current evidence as it is a large study, with a recruitment target of 2400 participants, and is multi‐centred, with multiple sites in Austria, as well as the Netherlands and New Zealand. </p> <p>Lastly, although outside the scope of this review, it is worthy of mention that the natriuretic peptides (NPs) have demonstrated prognostic value in atrial fibrillation (AF), and NP‐guided treatment also has the potential to be of benefit in the management of AF (<a href="./references#CD013015-bbs2-0043" title="HijaziZ , OldgrenJ , AnderssonU , ConnollySJ , EzekowitzMD , HohnloserSH , et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long‐term Anticoagulation Therapy (RE‐LY) substudy. Circulation2012;125(13):1605‐16. ">Hijazi 2012</a>). Brain natriuretic peptide (BNP) and N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) levels are elevated in AF patients (<a href="./references#CD013015-bbs2-0043" title="HijaziZ , OldgrenJ , AnderssonU , ConnollySJ , EzekowitzMD , HohnloserSH , et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long‐term Anticoagulation Therapy (RE‐LY) substudy. Circulation2012;125(13):1605‐16. ">Hijazi 2012</a>; <a href="./references#CD013015-bbs2-0073" title="PattonKK , HeckbertSR , AlonsoA , BahramiH , LimaJA , BurkeG , et al. N‐terminal pro‐B‐type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi‐Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart2013;99(24):1832‐6. ">Patton 2013</a>; <a href="./references#CD013015-bbs2-0086" title="SchnabelRB , LarsonMG , YamamotoJF , SullivanLM , PencinaMJ , MeigsJB , et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation2010;121(2):200. ">Schnabel 2010</a>; <a href="./references#CD013015-bbs2-0089" title="SilvetH , Young‐XuY , WalleighD . Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. American Journal of Cardiology2003;92(9):1124‐7. ">Silvet 2003</a>) and have been shown to be a strong independent predictor of incident AF, total and ischaemic stroke, mortality, and the burden of AF (<a href="./references#CD013015-bbs2-0044" title="HijaziZ , WallentinL , SiegbahnA , AnderssonU , ChristerssonC , EzekowitzJ , et al. N‐terminal pro–B‐type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). Journal of the American College of Cardiology2013;61(22):2274‐84. ">Hijazi 2013</a>; <a href="./references#CD013015-bbs2-0046" title="HijaziZ , WallentinL . Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation. Heart2019;105:353‐4. ">Hijazi 2019</a>; <a href="./references#CD013015-bbs2-0094" title="WangT , LarsonM , LevyD , BenjaminE , LeipE , OmlandT , et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine2004;350(7):655‐63. ">Wang 2004</a>). At present, an individual’s risk of stroke is predicted by a clinical risk score such as CHADS<sub>2</sub> or CHA<sub>2</sub>DS<sub>2</sub>‐VASc. These scores are based on well‐established clinical risk factors, and an individual's score is used as an indication of whether an oral anticoagulant should be introduced. However, these scores have only modest discriminating ability to predict which patients will have a stroke (<a href="./references#CD013015-bbs2-0033" title="FangMC , GoAS , ChangY , BorowskyL , PomernackiNK , SingerDE , et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. Journal of the American College of Cardiology2008;51(8):810‐5. ">Fang 2008</a>; <a href="./references#CD013015-bbs2-0055" title="LipGY , NieuwlaatR , PistersR , LaneDA , CrijnsHJ . Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor‐based approach: the euro heart survey on atrial fibrillation. Chest2010;137(2):263‐72. ">Lip 2010</a>). Biomarker based risk scores have been shown to improve risk stratification for stroke in AF beyond these scores, resulting in more accurate identification of those at high risk for thromboembolic events (<a href="./references#CD013015-bbs2-0045" title="HijaziZ , LindbäckJ , AlexanderJH , HannaM , HeldC , HylekEM , et al. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker‐based risk score for predicting stroke in atrial fibrillation. European Heart Journal2016;37(20):1582‐90. ">Hijazi 2016</a>). Thus, knowledge of patients' NP levels may allow for implementation of more intensive monitoring or primary prevention strategies, including oral anticoagulants, angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, statins and ablation therapy (<a href="./references#CD013015-bbs2-0043" title="HijaziZ , OldgrenJ , AnderssonU , ConnollySJ , EzekowitzMD , HohnloserSH , et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long‐term Anticoagulation Therapy (RE‐LY) substudy. Circulation2012;125(13):1605‐16. ">Hijazi 2012</a>). However, the efficacy of NP‐guided treatment in improving outcomes in AF patients is as of yet unproven, and randomised controlled trials, and ultimately meta‐analyses are required to explore the role NP‐guided treatment in this cohort. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013015-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013015-sec-0029"></div> <div class="table" id="CD013015-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Natriuretic peptide‐guided treatment compared to standard care for the prevention of cardiovascular events in patients without heart failure</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Natriuretic peptide‐guided treatment compared to standard care for the prevention of cardiovascular events in patients without heart failure</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients without heart failure<br/> <b>Setting:</b> any<br/> <b>Intervention:</b> natriuretic peptide‐guided treatment<br/> <b>Comparison:</b> standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with natriuretic peptide‐guided treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> <p>Follow‐up: 2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.04 to 3.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular deaths not available, so cardiac deaths used</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular hospitalisation (as defined by trialists)</p> <p>Follow‐up range:</p> <p>2 years to mean 4.2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/> (0.40 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1674<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (65 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: range 2 years to mean 4.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.60 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1354<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (36 to 81) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause hospitalisation (all occurrences)<br/> Follow‐up: range 2 years to mean 4.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.75 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1354<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>601 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>499 per 1000<br/> (457 to 553) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ventricular dysfunction (as defined by trialists)<br/> Assessed with Doppler echocardiography<br/> Follow‐up: mean 4.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/> (0.41 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1374<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ventricular dysfunction was defined by trialists as left ventricular dysfunction and heart failure. Left ventricular dysfunction (LVD) included all patients with asymptomatic left ventricular systolic dysfunction (LVSD) and/or asymptomatic left ventricular diastolic dysfunction (LVDD). Heart failure included all patients with LVD (LVSD and/or LVDD) and with symptoms of heart failure requiring emergency admission to hospital </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/> (36 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in NP level at the end of follow‐up<br/> Follow‐up: mean 4.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in NP level at the end of follow‐up was 9.52 pg/mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.06 pg/mL higher<br/> (15.07 lower to 6.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1374<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data come from <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013;</a> NP level was reported as BNP. <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> also reported change in NT‐proBNP after 1 year of treatment. However, these data were presented as median and interquartile range; therefore we could not calculate mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Imprecision: very wide 95% confidence interval, which includes the line of null effect and is consistent with the possibility of both important benefits and harms. The sample size is small. Downgraded by two levels. </p> <p><sup>b</sup>Risk of bias: both studies did not blind patients or personnel. Downgraded by one level. </p> <p><sup>c</sup>Imprecision: wide 95% confidence interval, which includes the line of null effect and is consistent with the possibility of important benefits and harms. Downgraded by one level. </p> <p><sup>d</sup>Risk of bias: downgraded by one level due to attrition bias as one study excluded from analysis patients who were lost to follow‐up and those who withdrew, who did not have at least one year of detailed follow‐up cost data. </p> <p><sup>e</sup>Risk of bias: echocardiographer and cardiologist reviewing end of study echo were blinded and diagnosis of ventricular dysfunction was based on clearly defined echocardiographic measures, which removed subjectivity in outcome assessment. Not downgraded. </p> <p><sup>f</sup>Imprecision: wide CIs that cross the line of no effect (zero) and include the possibility of the intervention causing both benefit and harm. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013015-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-sec-0117">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD013015-sec-0030"></div> <section id="CD013015-sec-0031"> <h3 class="title" id="CD013015-sec-0031">Description of the condition</h3> <p>Cardiovascular disease (CVD) refers to a wide group of conditions that affect the heart and blood vessels (<a href="./references#CD013015-bbs2-0097" title="World Health Organization. Cardiovascular diseases (CVDs). Fact Sheet Number 317, 2013. http://www.who.int/mediacentre/factsheets/fs317/en/index.html (accessed 8 January 2019). ">WHO 2013</a>); it is the leading cause of mortality and morbidity globally and remains the foremost cause of preventable death (<a href="./references#CD013015-bbs2-0084" title="SantulliG . Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. Journal of Cardiovascular Disease2013;1(1):2326‐3121. ">Santulli 2013</a>; <a href="./references#CD013015-bbs2-0098" title="World Health Organization. Cardiovascular diseases fact sheet. www.who.int/mediacentre/factsheets/fs317/en/ (accessed 21 July 2016). ">WHO 2016</a>). An estimated 17.5 million people died from CVD in 2012, representing 31% of all global deaths (<a href="./references#CD013015-bbs2-0098" title="World Health Organization. Cardiovascular diseases fact sheet. www.who.int/mediacentre/factsheets/fs317/en/ (accessed 21 July 2016). ">WHO 2016</a>). In Europe, close to half of all deaths are caused by CVD (<a href="./references#CD013015-bbs2-0068" title="NicholsM , TownsendN , ScarboroughP , RaynerM . Cardiovascular disease in Europe 2014: epidemiological update. European Heart Journal2014;35(42):2950‐9. ">Nichols 2014</a>), and the estimated cost to the EU economy is EUR 169 billion annually (<a href="./references#CD013015-bbs2-0041" title="Health Economics Research Centre. CVD costs in Europe: the economic burden of cardiovascular disease in the enlarged European Union. www.herc.ox.ac.uk/research/disease‐cost‐studies‐1/studies‐14/cvd‐costs‐in‐europe‐the‐economic‐burden‐of‐cardiovascular‐disease‐in‐the‐enlarged‐european‐union‐1 (accessed 21 July 2016). ">HERC 2012</a>). </p> <p>The prevalence of CVD is set to increase further as a result of the epidemic of obesity, diabetes, hypertension, and dyslipidaemia (disturbance in lipid metabolism leading to changes in plasma lipoprotein function and/or levels) (<a href="./references#CD013015-bbs2-0037" title="GoA , MozaffarianD , RogerV , BenjaminE , BerryJ , BlahaM , et al. Heart disease and stroke statistics. 2014 update: a report from the American Heart Association. Circulation2014;129(3):228‐92. ">Go 2014</a>; <a href="./references#CD013015-bbs2-0075" title="PiepoliM , HoesA , AgewallS , AlbusC , BrotonsC , CatapanoAL , et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal2016;37(29):2315‐81. ">Piepoli 2016</a>; <a href="./references#CD013015-bbs2-0084" title="SantulliG . Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. Journal of Cardiovascular Disease2013;1(1):2326‐3121. ">Santulli 2013</a>). One‐quarter of adults aged 50 years have at least one risk factor for the development of CVD (<a href="./references#CD013015-bbs2-0056" title="Lloyd‐JonesD , LeipE , LarsonM , D'AgostinoR , BeiserA , WilsonP , et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation2006;133(6):791‐8. ">Lloyd‐Jones 2006</a>). According to the American Heart Association, nearly 35% of adults in the USA have obesity (body mass index (BMI) ≥ 30 kg/m²), almost 40% have dyslipidaemia, 33% have hypertension, 8.3% have diabetes, and 38% have abnormal fasting glucose or prediabetes (<a href="./references#CD013015-bbs2-0037" title="GoA , MozaffarianD , RogerV , BenjaminE , BerryJ , BlahaM , et al. Heart disease and stroke statistics. 2014 update: a report from the American Heart Association. Circulation2014;129(3):228‐92. ">Go 2014</a>). Among people free of CVD at 50 years of age, more than half of men and nearly 40% of women will develop CVD during their remaining life span (<a href="./references#CD013015-bbs2-0056" title="Lloyd‐JonesD , LeipE , LarsonM , D'AgostinoR , BeiserA , WilsonP , et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation2006;133(6):791‐8. ">Lloyd‐Jones 2006</a>). Diabetes confers the highest lifetime risk for CVD of any single risk factor (<a href="./references#CD013015-bbs2-0056" title="Lloyd‐JonesD , LeipE , LarsonM , D'AgostinoR , BeiserA , WilsonP , et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation2006;133(6):791‐8. ">Lloyd‐Jones 2006</a>), with hypertension, dyslipidaemia, and obesity also identified as factors indicating increased risk (<a href="./references#CD013015-bbs2-0037" title="GoA , MozaffarianD , RogerV , BenjaminE , BerryJ , BlahaM , et al. Heart disease and stroke statistics. 2014 update: a report from the American Heart Association. Circulation2014;129(3):228‐92. ">Go 2014</a>; <a href="./references#CD013015-bbs2-0056" title="Lloyd‐JonesD , LeipE , LarsonM , D'AgostinoR , BeiserA , WilsonP , et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation2006;133(6):791‐8. ">Lloyd‐Jones 2006</a>; <a href="./references#CD013015-bbs2-0075" title="PiepoliM , HoesA , AgewallS , AlbusC , BrotonsC , CatapanoAL , et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal2016;37(29):2315‐81. ">Piepoli 2016</a>; <a href="./references#CD013015-bbs2-0084" title="SantulliG . Epidemiology of cardiovascular disease in the 21st century: updated numbers and updated facts. Journal of Cardiovascular Disease2013;1(1):2326‐3121. ">Santulli 2013</a>). </p> <p>CVD is a life course disease, commencing with risk factors (e.g. hypertension, dyslipidaemia) that over time may contribute to the development of subclinical disease (<a href="./references#CD013015-bbs2-0021" title="BerensonGS , SrinivasanSR , BaoW , NewmanWP , TracyRE , WattigneyWA . Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. New England Journal of Medicine1998;338(23):1650‐6. ">Berenson 1998</a>). Without proper management of risk factors, subclinical CVD more rapidly transitions to overt CVD, meaning that early identification of high‐risk patients is crucial for improving patient prognosis (<a href="./references#CD013015-bbs2-0051" title="KullerL , ShemanskiL , PsatyB , BorhaniN , GardinJ , HaanM , et al. Subclinical disease as an independent risk factor for cardiovascular disease. Circulation1995;92(4):720‐6. ">Kuller 1995</a>; <a href="./references#CD013015-bbs2-0098" title="World Health Organization. Cardiovascular diseases fact sheet. www.who.int/mediacentre/factsheets/fs317/en/ (accessed 21 July 2016). ">WHO 2016</a>). </p> <p>Traditional risk factor interventions for the prevention of CVD and cardiovascular events have brought about reductions in cardiovascular morbidity and mortality in at‐risk populations (<a href="./references#CD013015-bbs2-0030" title="EbrahimS , TaylorF , WardK , BeswickA , BurkeM , SmithD . Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD001561.pub3] ">Ebrahim 2011</a>; <a href="./references#CD013015-bbs2-0066" title="NadirMA , RekhrajS , WeiL , LimTK , DavidsonJ , MacDonaldTM , et al. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. Journal of the American College of Cardiology2012;60(11):960‐8. ">Nadir 2012</a>). Despite these efforts, a residual risk for the development of CVD remains that is not preventable by targeting traditional risk factors (<a href="./references#CD013015-bbs2-0071" title="OlsenMH , HansenTW , ChristensenMK , GustafssonF , RasmussenS , WachtellK , et al. N‐terminal pro‐brain natriuretic peptide, but not high sensitivity C‐reactive protein, improves cardiovascular risk prediction in the general population. European Heart Journal2007;28(11):1374‐81. ">Olsen 2007</a>; <a href="./references#CD013015-bbs2-0095" title="WangTJ , GonaP , LarsonMG , ToflerGH , LevyD , Newton‐ChehC , et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. New England Journal of Medicine2006;355(25):2631‐9. ">Wang 2006</a>). One study estimated that even among patients with optimal risk factor control, 43% of coronary events would still occur (<a href="./references#CD013015-bbs2-0024" title="ChiuveSE , McCulloughML , SacksFM , RimmEB . Healthy lifestyle factors in the primary prevention of coronary heart disease among men: benefits among users and nonusers of lipid‐lowering and antihypertensive medications. Circulation2006;1142(2):160‐7. ">Chiuve 2006</a>). In patients with diabetes, current approaches to cardiovascular risk factor management do not appear to attenuate the future risk of heart failure (<a href="./references#CD013015-bbs2-0078" title="RawshaniA , RawshaniA , FranzénS , SattarN , EliassonB , SvenssonA‐M , et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine2018;379(7):633‐44. ">Rawshani 2018</a>). Therefore, there is a clear gap between primary and secondary prevention of CVD that is not adequately addressed by the traditional risk factor approach. </p> </section> <section id="CD013015-sec-0032"> <h3 class="title" id="CD013015-sec-0032">Description of the intervention</h3> <p>The intervention in our review is the application of circulating brain natriuretic peptide (BNP) and N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) levels to risk‐stratify patients with established CVD, but without heart failure, for more intensive cardiovascular management. </p> <p>Biomarkers such as troponin 1, C‐reactive protein, and the natriuretic peptides (NPs) (BNP and NT‐proBNP) have emerged as potentially important adjuncts to traditional cardiovascular risk assessment (<a href="./references#CD013015-bbs2-0102" title="ZetheliusB , BerglundL , SundströmJ , IngelssonE , BasuS , LarssonA , et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. New England Journal of Medicine2008;358(20):2107‐16. ">Zethelius 2008</a>). BNP and NT‐proBNP have proven utility for the diagnosis and prognostication of patients with heart failure (<a href="./references#CD013015-bbs2-0026" title="ClericoA , EmdinM . Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clinical Chemistry2004;50(1):33‐50. ">Clerico 2004</a>; <a href="./references#CD013015-bbs2-0007" title="EurlingsL , vanPolP , KokW , vanWijkS , Lodewijks‐van der BoltC , BalkA . Management of chronic heart failure guided by individual N‐terminal pro–B‐type natriuretic peptide targets: results of the PRIMA (can PRo‐brain‐natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology2010;56(25):2090‐100. ">Eurlings 2010</a>; <a href="./references#CD013015-bbs2-0039" title="GroenningB , RaymondI , HildebrandtP , NilssonJ , BaumannM , PedersenF . Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N‐terminal pro‐brain natriuretic peptide concentrations in a large sample of the general population. Heart2004;90(3):297‐303. ">Groenning 2004</a>; <a href="./references#CD013015-bbs2-0009" title="JanuzziJ , RehmanS , MohammedA , BhardwajA , BarajasL , BarajasJ . Use of amino‐terminal pro–B‐type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. Journal of the American College of Cardiology2011;58(18):1881‐9. ">Januzzi 2011</a>; <a href="./references#CD013015-bbs2-0076" title="PonikowskiP , VoorsA , AnkerS , BuenoH , ClelandJ , CoatsA , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 14;37(27):2129‐200. ">Ponikowski 2016</a>), and a recent Cochrane Review found that BNP‐guided treatment for patients with heart failure may reduce the number of heart failure‐related hospitalisations (<a href="./references#CD013015-bbs2-0062" title="McLellanJ , HeneghanCJ , PereraR , ClementsAM , GlasziouPP , KearleyKE , et al. B‐type natriuretic peptide‐guided treatment for heart failure. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD008966.pub2] ">McLellan 2016</a>). These NPs have also demonstrated high independent strength in predicting CV events and mortality in patients without heart failure and in detecting left ventricular dysfunction (LVD) in both asymptomatic and symptomatic patients (<a href="./references#CD013015-bbs2-0025" title="ChristensonRH , GottdienerJS , KopWJ , SeligerSL . Dynamic cardiovascular risk assessment in elderly people: the role of repeated N‐terminal pro–B‐type natriuretic peptide testing. Journal of the American College of Cardiology2010;55(5):441‐50. ">Christenson 2010</a>; <a href="./references#CD013015-bbs2-0058" title="McDonaghT , RobbS , MurdochD , MortonJ , FordI , MorrisonC , et al. Biochemical detection of left‐ventricular systolic dysfunction. The Lancet1998;351(9095):9‐13. ">McDonagh 1998</a>; <a href="./references#CD013015-bbs2-0090" title="TarnowL , GallM , HansenB , HovindP , ParvingH . Plasma n‐terminal pro‐b‐type natriuretic peptide and mortality in type 2 diabetes. Diabetologia2006;49:2256–326. ">Tarnow 2006</a>; <a href="./references#CD013015-bbs2-0091" title="TonkinAM , BlankenbergS , KirbyA , ZellerT , ColquhounDM , Funke‐KaiserA , et al. Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: the LIPID biomarker study. International Journal of Cardiology2015;201:499‐507. ">Tonkin 2015</a>; <a href="./references#CD013015-bbs2-0094" title="WangT , LarsonM , LevyD , BenjaminE , LeipE , OmlandT , et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine2004;350(7):655‐63. ">Wang 2004</a>; <a href="./references#CD013015-bbs2-0096" title="WelshP , DoolinO , WilleitP , PackardC , MacfarlaneP , CobbeS , et al. N‐terminal pro‐B‐type natriuretic peptide and the prediction of primary cardiovascular events: results from 15‐year follow‐up of WOSCOPS. European Heart Journal2012;34(6):443‐50. ">Welsh 2012</a>). </p> <p>McDonagh and colleagues first proposed measurement of NP as a screening method for identification of left ventricular systolic dysfunction (LVSD) in the general population (<a href="./references#CD013015-bbs2-0058" title="McDonaghT , RobbS , MurdochD , MortonJ , FordI , MorrisonC , et al. Biochemical detection of left‐ventricular systolic dysfunction. The Lancet1998;351(9095):9‐13. ">McDonagh 1998</a>). In their study, they demonstrated that almost half of those diagnosed with LVSD on echocardiography were asymptomatic, and that NP levels were elevated in both asymptomatic and symptomatic patients. Normal BNP levels in this population were estimated to be &lt; 18 pg/mL, and other studies have shown that higher NP levels are associated with increased risk of CV events, mortality, and LVSD (<a href="./references#CD013015-bbs2-0047" title="KaraK , MahabadiAA , GeiselMH , LehmannN , KälschH , BauerM , et al. B‐type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events ‐ the Heinz Nixdorf Recall Study. Clinical Research in Cardiology2014;103(2):125‐32. ">Kara 2014</a>; <a href="./references#CD013015-bbs2-0058" title="McDonaghT , RobbS , MurdochD , MortonJ , FordI , MorrisonC , et al. Biochemical detection of left‐ventricular systolic dysfunction. The Lancet1998;351(9095):9‐13. ">McDonagh 1998</a>; <a href="./references#CD013015-bbs2-0094" title="WangT , LarsonM , LevyD , BenjaminE , LeipE , OmlandT , et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine2004;350(7):655‐63. ">Wang 2004</a>). Numerous subsequent studies have reiterated the effectiveness of NP screening for detecting ventricular dysfunction (<a href="./references#CD013015-bbs2-0023" title="BettiI , CastelliG , BarchielliA , BeligniC , BoscheriniV , DeLucaL , et al. The role of N‐terminal PRO‐brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE‐HF study. Journal of Cardiac Failure2009;15(5):377‐84. ">Betti 2009</a>; <a href="./references#CD013015-bbs2-0060" title="McGradyM , ReidC , ShielL , WolfeR , BoffaU , LiewD , et al. N‐terminal b‐type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluation of the Evolution of New‐Heart Failure Study (SCREEN‐HF). European Journal of Heart Failure2013;14:573‐80. ">McGrady 2013</a>; <a href="./references#CD013015-bbs2-0067" title="NgLL , LokeIW , DaviesJE , GeeranavarS , KhuntiK , StoneMA , et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptide. Journal of the American College of Cardiology2005;45(7):1043‐50. ">Ng 2005</a>). </p> <p>NP screening provides a feasible strategy by which heart failure may be detected much earlier in its natural history, before development of more advanced, symptomatic disease (<a href="./references#CD013015-bbs2-0059" title="McDonaghT . Screening for left ventricular dysfunction: a step too far?. Heart2002;88(Suppl 2):ii12‐ii14. ">McDonagh 2002</a>). However, widespread population screening is resource‐intensive and is unlikely to be cost‐effective. Several studies have demonstrated the cost‐effectiveness of NP screening for LVD in high‐risk subgroups, such as those with hypertension, ischaemic heart disease, or diabetes (<a href="./references#CD013015-bbs2-0040" title="HeidenreichPA , GubensMA , FonarowGC , KonstamMA , StevensonLW , ShekellePG . Cost‐effectiveness of screening with B‐type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. Journal of the American College of Cardiology2004;43(6):1019‐26. ">Heidenreich 2004</a>; <a href="./references#CD013015-bbs2-0052" title="LedwidgeMT , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. ">Ledwidge 2015</a>; <a href="./references#CD013015-bbs2-0069" title="NielsenOW , McDonaghTA , RobbSD , DargieHJ . Retrospective analysis of the cost‐effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. Journal of the American College of Cardiology2003;41(1):113‐20. ">Nielsen 2003</a>). </p> <p>Ledwidge and colleagues were the first to integrate community NP screening for risk stratification of patients with intensive diagnostic and therapeutic strategies (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). In this study, patients with elevated BNP received multi‐dimensional, collaborative care between the primary care physician and the cardiologist. This collaborative care approach reduced rates of LVD and heart failure, as well as emergency hospitalisations for major adverse cardiovascular events (MACE). In a subsequent study of patients with diabetes, Huelsmann and coworkers used elevated NT‐proBNP to select patients for usual care, or an intervention involving cardiologist‐led up‐titration of renin‐angiotensin‐aldosterone system (RAAS)‐modifying therapies and beta‐blockers to maximum doses (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>). Although there is heterogeneity in the populations studied, the interventions applied, and the NP test thresholds used, NP‐guided treatment for prevention of heart failure has been incorporated into guidelines, including the 2017 American Heart Association/American College of Cardiology guidelines on Heart Failure (<a href="./references#CD013015-bbs2-0100" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , ColvinMM , et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation2017;136:137‐61. ">Yancy 2017</a>), and the 2017 Canadian Cardiovascular Society Heart Failure Management Guidelines (<a href="./references#CD013015-bbs2-0032" title="EzekowitzJA , O'MearaE , McDonaldMA , AbramsH , ChanM , DucharmeA , et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology2017;33(11):1342‐433. ">Ezekowitz 2017</a>). </p> <p>This review sought to determine whether NP‐guided treatment for people with cardiovascular risk factors and without heart failure will improve morbidity and mortality versus standard care (defined as local guideline‐based care, including modification of pharmacological, educational, and lifestyle interventions, without accounting for the NP level). </p> </section> <section id="CD013015-sec-0033"> <h3 class="title" id="CD013015-sec-0033">How the intervention might work</h3> <p>Modulation of traditional risk factors (e.g. hypertension, dyslipidaemia) has improved cardiovascular outcomes in at‐risk individuals, but residual risk remains (<a href="./references#CD013015-bbs2-0030" title="EbrahimS , TaylorF , WardK , BeswickA , BurkeM , SmithD . Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD001561.pub3] ">Ebrahim 2011</a>; <a href="./references#CD013015-bbs2-0050" title="KrogsbøllL , JørgensenK , Grønhøj LarsenC , GøtzscheP . General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database of Systematic Reviews2012, Issue 10. [DOI: 10.1002/14651858.CD009009.pub2] ">Krogsbøll 2012</a>). </p> <p>BNP and the biologically inactive NT‐proBNP are members of the NP family that are released by cardiomyocytes in response to various stimuli, including myocyte stretch due to volume expansion and pressure overload, ischaemia (reduced coronary blood supply to the heart), fibrosis, and inflammation (<a href="./references#CD013015-bbs2-0057" title="MaedaK , TsutamotoT , WadaA , HisanagaT , KinoshitaM . Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end‐diastolic pressure in patients with symptomatic left ventricular dysfunction. American Heart Journal1998;135(5):825‐32. ">Maeda 1998</a>; <a href="./references#CD013015-bbs2-0074" title="PhelanD , WatsonC , MartosR , CollierP , PatleA , DonnellyS , et al. Modest elevation in BNP in asymptomatic hypertensive patients reflects sub‐clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One2012;7(11):e49259. ">Phelan 2012</a>; <a href="./references#CD013015-bbs2-0083" title="SabatineM , MorrowD , deLemosJ , OmlandT , DesaiM , TanasijevicM , et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. Journal of the American College of Cardiology2004;44(10):1988‐95. ">Sabatine 2004</a>; <a href="./references#CD013015-bbs2-0101" title="YoshimuraM , YasueH , OkumuraK , OgawaH , JougasakiM , MukoyamaM , et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation1993;87:464‐9. ">Yoshimura 1993</a>). As NPs indicate a physiological response to established cardiovascular stress, strain, or damage, they add predictive power to conventional risk factors, which largely reflect the potential for cardiovascular insult (<a href="./references#CD013015-bbs2-0060" title="McGradyM , ReidC , ShielL , WolfeR , BoffaU , LiewD , et al. N‐terminal b‐type natriuretic peptide and the association with left ventricular diastolic function in a population at high risk of incident heart failure: results of the SCReening Evaluation of the Evolution of New‐Heart Failure Study (SCREEN‐HF). European Journal of Heart Failure2013;14:573‐80. ">McGrady 2013</a>; <a href="./references#CD013015-bbs2-0072" title="OnoderaM , NakamuraM , TanakaF , TakahashiT , MakitaS , IshisoneT , et al. Plasma b‐type natriuretic peptide is useful for cardiovascular risk assessment in community‐based diabetes subjects: comparison with albuminuria. International Heart Journal2012;53(3):176‐81. ">Onodera 2012</a>; <a href="./references#CD013015-bbs2-0090" title="TarnowL , GallM , HansenB , HovindP , ParvingH . Plasma n‐terminal pro‐b‐type natriuretic peptide and mortality in type 2 diabetes. Diabetologia2006;49:2256–326. ">Tarnow 2006</a>; <a href="./references#CD013015-bbs2-0094" title="WangT , LarsonM , LevyD , BenjaminE , LeipE , OmlandT , et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. New England Journal of Medicine2004;350(7):655‐63. ">Wang 2004</a>). </p> <p>Increases in plasma BNP/NT‐proBNP concentration have diagnostic and prognostic implications for selected populations, as demonstrated initially in heart failure, and subsequently in early‐stage and asymptomatic disease (<a href="./references#CD013015-bbs2-0031" title="EurlingsL , vanPolP , KokW , vanWijkS , Lodewijks‐van der BoltC , BalkA , et al. Management of chronic heart failure guided by individual n‐terminal pro‐b‐type natriuretic peptide targets: results of the PRIMA (Can PRo‐brain‐natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. Journal of the American College of Cardiology2010;56(25):2090‐100. ">Eurlings 2010</a>; <a href="./references#CD013015-bbs2-0035" title="GardnerR , OzalpF , MurdayA , RobbS , McDonaghT . N‐terminal pro‐brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. European Heart Journal2003;24:1735–43. ">Gardner 2003</a>; <a href="./references#CD013015-bbs2-0048" title="KearleyK , WrightF , TyndelS , RobertsN , PereraR , GlasziouP , et al. B‐type natriuretic peptide‐guided treatment for heart failure. Cochrane Database of Systematic Reviews2011, Issue 1. [DOI: 10.1002/14651858.CD008966] ">Kearley 2011</a>). In some studies, NPs have shown superiority over traditional CVD risk factors, such as hypercholesterolaemia and hypertension, for identifying those at risk of heart failure (<a href="./references#CD013015-bbs2-0027" title="ClericoA , FontanaM , ZywL , PassinoC , EmdinM . Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the n‐terminal part of the pro‐peptide of BNP immunoassays in chronic and acute heart failure: a systematic review. Clinical Chemistry2007;53(5):813‐22. ">Clerico 2007</a>), acute coronary syndrome (<a href="./references#CD013015-bbs2-0036" title="GlaserR , PeacockWF , WuAH , MullerR , MöckelM , AppleFS . Placental growth factor and b‐type natriuretic peptide as independent predictors of risk from a multi‐biomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes assessed With cardiac biomarkers [ARROW]) study. American Journal of Cardiology2011;107(6):821‐6. ">Glaser 2011</a>; <a href="./references#CD013015-bbs2-0087" title="SciricaBM , SabatineMS , JarolimP , MurphySA , deLemosJL , BraunwaldE , et al. Assessment of multiple cardiac biomarkers in non‐ST‐segment elevation acute coronary syndromes: observations from the MERLIN‐TIMI 36 Trial. European Heart Journal2011;32(6):697‐705. ">Scirica 2011</a>), and coronary heart disease (<a href="./references#CD013015-bbs2-0064" title="MishraRK , BeattyAL , JaganathR , ReganM , WuAHB , WhooleyMA . B‐type natriuretic peptides for the prediction of cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Journal of the American Heart Association2014;3(4):1‐9. ">Mishra 2014</a>). Thus, measurement of NP levels to identify those at greatest risk of cardiovascular events, followed by targeted intensive risk reduction (including pharmacotherapy, diagnostic and investigation strategies, and lifestyle and educational interventions), may reduce the occurrence of mortality and morbidity, including MACE, in this population. Although it is the most commonly used endpoint for cardiovascular research, there is no standard definition for MACE, and individual outcomes used to make this composite endpoint vary by study (<a href="./references#CD013015-bbs2-0049" title="KipKE , HollabaughK , MarroquinOC , WilliamsDO . The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention. Journal of the American College of Cardiology2008;51(7):701‐7. ">Kip 2008</a>). </p> </section> <section id="CD013015-sec-0034"> <h3 class="title" id="CD013015-sec-0034">Why it is important to do this review</h3> <p>NP‐guided treatment for optimisation of heart failure management is well established (<a href="./references#CD013015-bbs2-0076" title="PonikowskiP , VoorsA , AnkerS , BuenoH , ClelandJ , CoatsA , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 14;37(27):2129‐200. ">Ponikowski 2016</a>; <a href="./references#CD013015-bbs2-0099" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDEJr , DraznerMH , et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation2013;128(16):240‐327. ">Yancy 2013</a>), and this is the topic of another Cochrane Review (<a href="./references#CD013015-bbs2-0062" title="McLellanJ , HeneghanCJ , PereraR , ClementsAM , GlasziouPP , KearleyKE , et al. B‐type natriuretic peptide‐guided treatment for heart failure. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD008966.pub2] ">McLellan 2016</a>). Evidence for the use of NPs to identify and deliver a targeted intervention to an at‐risk population is emerging, but this approach to CVD and heart failure prevention is not yet part of routine clinical care. </p> <p>The 2017 Canadian Cardiovascular Society Heart Failure Management Guidelines suggest that in individuals at risk for development of heart failure (HF), "BNP &gt; 50 pg/mL or NT‐proBNP &gt; 125 pg/mL should prompt a request for specialist consultation and imaging, and/or initiation or intensification of neurohormonal blocking agents and lifestyle interventions" (<a href="./references#CD013015-bbs2-0032" title="EzekowitzJA , O'MearaE , McDonaldMA , AbramsH , ChanM , DucharmeA , et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology2017;33(11):1342‐433. ">Ezekowitz 2017</a>)<i>.</i> The 2017 American Guidelines for the Management of Heart Failure issued a 'moderate' recommendation that "for patients at risk of developing heart failure, NP‐based screening followed by team‐based care can be useful to prevent the development of left ventricular dysfunction (systolic or diastolic) or new‐onset heart failure" (<a href="./references#CD013015-bbs2-0100" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , ColvinMM , et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation2017;136:137‐61. ">Yancy 2017</a>). </p> <p>Due to the scarcity of scientific evidence and limited clinical experience in this area, it is difficult for guidelines to provide physicians with a clear consensus or specific recommendations on NP screening. In this review, we would like to collate and, through meta‐analysis, strengthen the existing body of evidence for this approach to CVD prevention, thereby allowing clearer recommendations to be made. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013015-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-sec-0122">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013015-sec-0035"></div> <p>To assess the effects of natriuretic peptide (NP)‐guided treatment for people with cardiovascular risk factors and without heart failure. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013015-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-sec-0123">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013015-sec-0036"></div> <section id="CD013015-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013015-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials (RCTs).</p> </section> <section id="CD013015-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults (≥ 18 years of age) with risk factors for development of CVD. We considered the following risk factors. </p> <p> <ul id="CD013015-list-0001"> <li> <p>Hypertension.</p> </li> <li> <p>Dyslipidaemia.</p> </li> <li> <p>Obesity (BMI ≥ 30 kg/m²).</p> </li> <li> <p>Metabolic syndrome.</p> </li> <li> <p>Vascular disease.</p> </li> <li> <p>Diabetes mellitus.</p> </li> <li> <p>Atrial fibrillation.</p> </li> <li> <p>Valvular heart disease.</p> </li> <li> <p>Elevated levels of NP, defined as BNP &gt; 35 pg/mL, or NT‐proBNP &gt; 125 pg/mL, or both (as considered by the European Society of Cardiology to be the upper limit of normal in the non‐acute heart failure setting (<a href="./references#CD013015-bbs2-0076" title="PonikowskiP , VoorsA , AnkerS , BuenoH , ClelandJ , CoatsA , et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal 14;37(27):2129‐200. ">Ponikowski 2016</a>)). We included NP measured by any assay. </p> </li> </ul> </p> <p>We did not consider lifestyle risk factors, such as sedentary lifestyle, diet, smoking, and alcohol intake. We included all healthcare settings (i.e. hospital, community). We excluded people with symptomatic heart failure at baseline, diagnosed by an established reference standard such as echocardiography, cardiac magnetic resonance imaging, or specialist opinion based on reference criteria (e.g. Framingham) (<a href="./references#CD013015-bbs2-0061" title="McKeeAP , CastelliWP , McNamaraPM , KannelWB . The natural history of congestive heart failure: the Framingham Study. New England Journal of Medicine1971;285(26):1441‐6. ">McKee 1971</a>), or a combination of these. At baseline, we excluded people who were being investigated for a possible diagnosis of symptomatic heart failure and people with any evidence of asymptomatic left ventricular systolic dysfunction (left ventricular ejection fraction &lt; 50%) at baseline. We contacted study authors to obtain data on subgroups outlined in our protocol; however we did not receive additional data from these authors. </p> </section> <section id="CD013015-sec-0040"> <h4 class="title">Types of interventions</h4> <p>We included RCTs comparing NP‐based screening (to identify patients at increased risk of developing a cardiovascular event) and subsequent NP‐guided treatment versus standard care. NP‐guided treatment includes modification and optimisation of pharmacological therapy (as defined by trialists), diagnostic and investigation strategies, and educational and lifestyle interventions based on NP levels, that is, supplementary to care provided in the control group. We included studies that involved any element of NP‐guided treatment. We defined standard care as local guideline‐based care, including modification of pharmacological, educational, and lifestyle interventions, without accounting for the participant's NP level. </p> </section> <section id="CD013015-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD013015-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013015-list-0002"> <li> <p>Cardiovascular mortality (as defined by trialists)</p> </li> <li> <p>Cardiovascular hospitalisation (as defined by trialists)</p> </li> </ul> </p> </section> <section id="CD013015-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013015-list-0003"> <li> <p>All‐cause mortality</p> </li> <li> <p>All‐cause hospitalisation (all occurrences)</p> </li> <li> <p>Ventricular dysfunction (as defined by trialists)</p> </li> <li> <p>Change in NP level at completion of follow‐up</p> </li> </ul> </p> <p>We used the definitions employed by investigators of the study under consideration.</p> </section> </section> </section> <section id="CD013015-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013015-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist from the Cochrane Heart Group conducted systematic searches of the following databases for RCTs without language, publication year, or publication status restrictions (all searches conducted 9 July 2019; search strategies provided in <a href="./appendices#CD013015-sec-0098">Appendix 1</a>). </p> <p> <ul id="CD013015-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 7), in the Cochrane Library. </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily, and MEDLINE (Ovid, 1946 to 8 July 2019). </p> </li> <li> <p>Embase (Ovid, 1980 to 2019 week 27).</p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science (CPCI‐S) Web of Science (Thomson Reuters, 1990 to 9 July 2019). </p> </li> </ul> </p> <p>The Information Specialist applied the Cochrane sensitivity‐maximising RCT filter to MEDLINE (Ovid) and adaptations of it to Embase and Web of Science (<a href="./references#CD013015-bbs2-0053" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). </p> <p>We also conducted searches of ClinicalTrials.gov (<a href="http://www.ClinicalTrials.gov" target="_blank">www.ClinicalTrials.gov</a>) (9 July 2019), the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) Search Portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>) (9 July 2019), and the EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu" target="_blank">www.clinicaltrialsregister.eu</a>) (14 July 2019) for ongoing or unpublished trials. </p> </section> <section id="CD013015-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all primary studies and reviewed articles for additional references. We checked for retraction statements and errata among included studies but found none. </p> </section> </section> <section id="CD013015-sec-0047"> <h3 class="title" id="CD013015-sec-0047">Data collection and analysis</h3> <section id="CD013015-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (FR, CS) independently screened titles and abstracts of articles obtained in the search results and coded them as ‘retrieve' (eligible or potentially eligible/unclear) or ‘do not retrieve'. We retrieved the full‐text study reports. Two review authors (FR, CS) independently screened the full‐text articles for all potentially relevant studies, identified studies for final inclusion, and identified and recorded reasons for exclusion of ineligible studies. We resolved disagreements through discussion and, when required, we consulted a third review author (CR). When necessary, we contacted trial authors to clarify a study's eligibility. We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD013015-fig-0001">Figure 1</a>), along with a <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011583.pub2/references#CD011583-sec2-0020" target="_blank">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD013015-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flow diagram." data-id="CD013015-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> </div> </section> <section id="CD013015-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (CS, RBP) independently performed data extraction using a data collection form based on the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013015-bbs2-0042" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). The form had been piloted by one study in the review (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). One review author (CS) extracted the following study characteristics from included studies. </p> <p> <ul id="CD013015-list-0005"> <li> <p>Methods: study design, total duration of study, details of any run‐in period, number of study centres and locations, study setting, and date of study. </p> </li> <li> <p>Participants: number of participants randomised, number of participants completing the study period, and number of participant withdrawals; mean age, age range, gender, severity of condition (as defined by trialists), diagnostic criteria, inclusion criteria, and exclusion criteria. </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications.</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected and time points reported.</p> </li> <li> <p>Notes: funding for trial and notable conflicts of interest of trial authors.</p> </li> </ul> </p> <p>Two review authors (CS, RBP) independently extracted outcome data from included studies. We resolved disagreements by reaching consensus or by involving a third review author (CR). One review author (CS) transferred data into the Review Manager 5 (RevMan 5) file (<a href="./references#CD013015-bbs2-0081" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>), and another review author (FR) double‐checked the data for accuracy. We double‐checked that data were entered correctly by comparing data presented in the systematic review against the study reports. A second review author (FR) spot‐checked trial characteristics for accuracy against the trial report. </p> </section> <section id="CD013015-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (CS, RBP) independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, and provided a summary judgement for each study (<a href="./references#CD013015-bbs2-0042" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). We resolved disagreements by discussion or by consultation with another review author (CR). We assessed risk of bias according to the following domains. </p> <p> <ul id="CD013015-list-0006"> <li> <p>Random sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants and personnel.</p> </li> <li> <p>Blinding of outcome assessment.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other bias.</p> </li> </ul> </p> <p>We judged each potential source of bias as high, low, or unclear, and provided a quote from the study report together with a justification for our judgement in the ‘Risk of bias' table. We summarised ‘Risk of bias' judgements across different studies for each of the domains listed. When we obtained information on risk of bias related to unpublished data or correspondence with a trialist, we noted this in the ‘Risk of bias' table. When considering treatment effects, we took into account the risk of bias for studies that contributed to that outcome. We had planned to undertake sensitivity analysis by excluding studies that were at high or unclear risk of bias for random sequence generation, allocation concealment, and incomplete data. However, due to the small number of included studies, this was not possible. </p> <section id="CD013015-sec-0051"> <h5 class="title">Assessment of bias in conducting the review</h5> <p>We conducted the review according to the published protocol and reported any deviations from it in the <a href="#CD013015-sec-0112">Differences between protocol and review</a> section of the review. </p> </section> </section> <section id="CD013015-sec-0052"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we used the numbers of events in intervention and control groups for each trial to calculate the Mantel‐Haenszel risk ratio (RR) with 95% confidence intervals (CIs). </p> <p>For continuous outcomes, we converted data into mean differences (MDs) and presented them with 95% CIs, as per the guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013015-bbs2-0042" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>). </p> <p>We intended to use standardised mean differences (SMDs) to combine data when trials used different scales to measure the same variable. However, we found no such data in our included trials and we did not use SMDs. </p> <p>Where applicable we described skewed data reported as medians and interquartile ranges (without variance data) narratively within the results text. </p> </section> <section id="CD013015-sec-0053"> <h4 class="title">Unit of analysis issues</h4> <p>The review presents no issues related to the unit of analysis, as we have included only individually randomised trials with one comparator and one control arm each, and outcomes were measured at single time points only. If in future updates of this review we encounter trials with multiple intervention arms, or trials that report outcomes at different time points, we will follow methodological guidance provided by <a href="./references#CD013015-bbs2-0029" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9. Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>. </p> </section> <section id="CD013015-sec-0054"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing, we contacted authors/investigators to verify critical study characteristics and to request further information. </p> </section> <section id="CD013015-sec-0055"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity visually and by using the I² statistic. We conducted a fixed‐effect meta‐analysis when no heterogeneity was present. When we identified substantial heterogeneity (I² &gt; 50%), we planned to employ a random‐effects model and to explore possible causes by conducting prespecified subgroup analyses (<a href="./references#CD013015-bbs2-0082" title="RyanR . Heterogeneity and subgroup analyses in Cochrane Consumers and Communication Group reviews: planning the analysis at protocol stage. cccrg.cochrane.org (accessed 9 April 2018). ">Ryan 2016</a>; detailed in <a href="#CD013015-sec-0059">Subgroup analysis and investigation of heterogeneity</a>). However, we did not identify substantial heterogeneity for any outcomes; therefore this was not necessary. We described clinical and methodological heterogeneity narratively. </p> </section> <section id="CD013015-sec-0056"> <h4 class="title">Assessment of reporting biases</h4> <p>If we had been able to pool more than 10 trials, we would have created and examined a funnel plot to explore possible small‐study bias for the primary outcomes (<a href="./references#CD013015-bbs2-0088" title="SedgwickP . Selection bias versus allocation bias. British Medical Journal2013;346:f1342. ">Sedgwick 2013</a>). However, due to the small number of included trials, we were unable to do this. </p> </section> <section id="CD013015-sec-0057"> <h4 class="title">Data synthesis</h4> <p>We employed a fixed‐effect Mantel‐Haenszel model for calculating RRs for pooled outcomes, as substantial heterogeneity was not present for any of the outcomes (I² &lt; 50%). Had we identified substantial heterogeneity for outcomes, we had planned to use a random‐effects model (see <a href="#CD013015-sec-0055">Assessment of heterogeneity</a> above). </p> <section id="CD013015-sec-0058"> <h5 class="title">'Summary of findings' table</h5> <p>We created <a href="./full#CD013015-tbl-0001">summary of findings Table for the main comparison</a> by using the following primary and secondary outcomes: cardiovascular mortality (as defined by trialists), cardiovascular hospitalisation (as defined by trialists), all‐cause mortality, all‐cause hospitalisation (all occurrences), ventricular dysfunction (as defined by trialists), and change in NP level at completion of follow‐up. </p> <p>We used the five GRADE considerations (risk of bias, inconsistency, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence as it relates to studies that contributed data to the analyses for prespecified outcomes. We used methods and recommendations as described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013015-bbs2-0042" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8. Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Higgins 2017</a>), along with GRADEpro GDT software (<a href="./references#CD013015-bbs2-0038" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>). Two review authors (CS, RBP) independently assessed the quality of evidence. We resolved disagreements by reaching consensus or by involving a third review author (FR). We used footnotes to document our justification for decisions to downgrade the quality of evidence. </p> </section> </section> <section id="CD013015-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses for the primary outcome.</p> <p> <ul id="CD013015-list-0007"> <li> <p>Age (≥ 65 years vs &lt; 65 years).</p> </li> <li> <p>Gender.</p> </li> <li> <p>Diabetes mellitus.</p> </li> <li> <p>Obesity (BMI ≥ 30 kg/m² vs BMI &lt; 30 kg/m²).</p> </li> <li> <p>Atrial fibrillation versus non‐atrial fibrillation.</p> </li> <li> <p>Valvular heart disease versus non‐valvular heart disease.</p> </li> <li> <p>Ischaemic heart failure versus non‐ischaemic heart failure.</p> </li> <li> <p>NP levels at baseline for classification of subgroups (BNP &lt; 50 pg/mL and NT‐proBNP &lt; 125 pg/mL; BNP ≥ 50 pg/mL and NT‐proBNP ≥ 125 pg/mL). These subgroups represent the cut‐off point specified by the 2017 Canadian Cardiovascular Society Heart Failure Management guidelines for implementation of strategies to prevent heart failure (<a href="./references#CD013015-bbs2-0032" title="EzekowitzJA , O'MearaE , McDonaldMA , AbramsH , ChanM , DucharmeA , et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology2017;33(11):1342‐433. ">Ezekowitz 2017</a>) (please note that this subgroup was modified post hoc to reflect updates from the 2017 guidelines; see <a href="#CD013015-sec-0112">Differences between protocol and review</a>). </p> </li> <li> <p>Renal function (estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m² or &lt; 60 mL/min/1.73 m² as measured by the Cockcroft and Gault or Modification of Diet in Renal Disease (MDRD) formula). </p> </li> </ul> </p> <p>Older age, female gender, and diabetes are associated with higher NP levels (<a href="./references#CD013015-bbs2-0079" title="RaymondI , GroenningB , HildebrandtP , NilssonJ , BaumannM , TrawinskiJ , et al. The influence of age, sex and other variables on the plasma level of n‐terminal pro brain natriuretic peptide in a large sample of the general population. Heart2003;89(7):745‐51. ">Raymond 2003</a>; <a href="./references#CD013015-bbs2-0093" title="WangT , LarsonM , LevyD , LeipE , BenjaminE , WilsonP , et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. American Journal of Cardiology2002;90(3):254‐8. ">Wang 2002</a>). </p> <p>Due to the paucity of data, we could not conduct most of our planned subgroup analyses. We described the characteristics of included trials according to methods, participants, interventions, and outcomes to establish clinical and methodological heterogeneity across included trials narratively. We were able to perform subgroup analysis based on NP levels at baseline (according to the post hoc modified subgroup; see <a href="#CD013015-sec-0112">Differences between protocol and review</a>). </p> <p>We included the primary outcome cardiovascular hospitalisation in the subgroup analysis. We were unable to perform subgroup analysis on the other primary outcome ‐ cardiovascular mortality ‐ as only one study reported this outcome. Post hoc, we considered performing subgroup analysis on the secondary outcomes; however we did not have sufficient data to do this. We used the formal statistical test for heterogeneity across subgroups based on the random‐effects model to test for subgroup interactions (<a href="http://cochranelibrary-wiley.com/doi/10.1002/14651858.CD012952/full#CD012952-bbs2-0007" target="_blank">Borenstein 2008</a>), and we used caution in interpreting subgroup analyses, as advised in Section 9.6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013015-bbs2-0029" title="DeeksJJ , HigginsJP , Altman DG(editors) , on behalf of the Cochrane Statistical Methods Group. Chapter 9. Analysing data and undertaking meta‐analyses. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from www.training.cochrane.org/handbook. ">Deeks 2017</a>). </p> </section> <section id="CD013015-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out sensitivity analyses by including only studies at low risk of bias for random sequence generation, allocation concealment, and incomplete data. However, an insufficient number of studies met the inclusion criteria of the review, so we could not do this. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013015-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013015-sec-0061"></div> <section id="CD013015-sec-0062"> <h3 class="title">Description of studies</h3> <section id="CD013015-sec-0063"> <h4 class="title">Results of the search</h4> <p>Through the database searches, we retrieved 14,462 records, and via a search of clinical trial registries, we retrieved 1034 records. After de‐duplication, we screened 10,193 records by title and abstract. Of these, 10,156 records did not meet the inclusion criteria, and we excluded them. We assessed the remaining 37 records in full text for eligibility and excluded 22 of them. We assessed 15 reports of four studies as eligible. Two studies (10 reports) were ongoing. We included five reports of two studies in the qualitative synthesis and three reports of two studies in the quantitative synthesis, with one additional record later sourced with data from trialists. The flow of studies is displayed in <a href="#CD013015-fig-0001">Figure 1</a>. </p> </section> <section id="CD013015-sec-0064"> <h4 class="title">Included studies</h4> <section id="CD013015-sec-0065"> <h5 class="title">Methods</h5> <p>Both of the included studies (reported in three references) were RCTs (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Both studies were conducted in Europe; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> was a single‐centre study conducted in Ireland, and <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> was conducted in Austria with patients cared for at two sites. Both studies had one comparison arm and compared NP‐guided treatment to standard care. Study duration ranged from two years in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> to mean 4.3 years in <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>. One study measured BNP (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>), and the other measured NT‐proBNP (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>). Full reports were available for both studies, and we obtained additional information for both studies through direct contact with the study authors. </p> </section> <section id="CD013015-sec-0066"> <h5 class="title">Participants</h5> <p><a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> was a pragmatic RCT involving one specialist centre and 39 general practices in the catchment area of a large teaching hospital. The trial recruited 1374 patients (677 in control group and 697 in intervention group). Participants included adults older than 40 years of age with a history of one or more of the following: hypertension, hyperlipidaemia, obesity, vascular disease (coronary artery disease, cerebrovascular disease, and peripheral vascular disease), diabetes mellitus, arrhythmia requiring therapy, or moderate to severe valvular disease. Patients who had symptoms of heart failure or established evidence of left ventricular systolic dysfunction were excluded. The mean age of participants was 65.4 years in the control group and 64.1 years in the intervention group, and more female than male participants were included (55.7% in the control group and 53.7% in the intervention group). </p> <p>In <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, data for the outcomes all‐cause hospitalisation and all‐cause mortality were derived from a subanalysis, which included a subsample of participants from the primary analysis. A total of 1054 participants were included (522 in the control group and 532 in the intervention group). The median age of participants was 65.8 years, and the mean duration of follow‐up was 4.3 years. Characteristics of participants in the subsample closely mirrored the full sample, although a marginally higher proportion of patients with hypertension at baseline were included in the subsample. </p> <p><a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> was an RCT in which all participants (control and intervention groups) were cared for at a specialist diabetic outpatient clinic, with intervention group participants attending additional appointments at a cardiac outpatient clinic of a different hospital. A total of 300 participants with type 2 diabetes and NT‐proBNP &lt; 125 pg/mL were randomised (150 in control group and 150 in intervention group). Patients with established evidence of left ventricular systolic dysfunction (LVSD) were excluded. The mean age of participants was 67.2 years in the control group and 67.8 years in the intervention group. Slightly fewer female than male participants were included (43.3% in the control group and 41.3% in the intervention group). </p> </section> <section id="CD013015-sec-0067"> <h5 class="title">Interventions</h5> <p>The components of the interventions delivered in both studies differed. In one study, participants in the control group received standard care defined as routine review by their primary care physician at least annually and specialist care as required (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). In the intervention group, BNP results were made available to the participants’ primary care physician, and patients with a BNP result of ≥ 50 pg/mL were referred to a specialist cardiovascular centre. Intervention group patients with a BNP result of &lt; 50 pg/mL received the same care as those in the control group but with disclosure of BNP values to patients and their primary care physician. Participants with a BNP level of ≥ 50 pg/mL underwent echocardiography and review by a cardiologist at the study centre, who decided on further investigation and management. The intervention in participants with BNP ≥ 50 pg/mL was multi‐dimensional and included optimisation of therapy (no predefined protocol), investigation and treatment of abnormalities detected on echocardiography, lifestyle advice, and counselling regarding medication adherence. </p> <p>In the second study, control group participants received standard care at a diabetes care unit with appointments every three months over a 12‐month period (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>). In addition to usual care, the intervention group attended visits at a cardiac outpatient clinic where RAAS antagonists and beta‐blockers were up‐titrated to maximum tolerated doses in a predefined manner. </p> <p>Distinct differences were evident in the content of the interventions delivered in both studies. In <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, intervention group patients with elevated BNP received multi‐dimensional care. By contrast, the intervention delivered to the intervention group in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> focused solely upon up‐titration of RAAS antagonists and beta‐blockers to maximum doses. Despite differences in interventional components, both interventions focused on optimisation of therapy, and both studies observed increased use of RAAS‐modifying therapy. Thus, we decided to perform meta‐analysis. However, the heterogeneity of the interventions must be kept in mind when effects of the interventions are interpreted. </p> </section> <section id="CD013015-sec-0068"> <h5 class="title">Outcomes</h5> <p>Both studies reported the following outcomes: cardiovascular hospitalisation (secondary outcome in both studies); all‐cause hospitalisation (secondary outcome in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; not a prespecified outcome in <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> but data available); all‐cause mortality (not a prespecified outcome in either study but data provided); and change in NP level at the end of follow‐up (secondary outcome in both studies). Meta‐analysis was performed for each of these outcomes, except for change in NP level at the end of follow‐up (different NPs used in each study). One study reported cardiovascular mortality (not a prespecified outcome) (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>). One study included the outcome ventricular dysfunction as a primary outcome (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). In this study, trialists defined ventricular dysfunction as left ventricular dysfunction (any patient with asymptomatic LVSD and/or asymptomatic left ventricular diastolic dysfunction (LVDD)) with or without heart failure (defined as any patient with LVD (LVSD and/or LVDD) and with symptoms of heart failure requiring emergency admission to hospital). We considered this outcome definition to be appropriate to our predefined outcomes as ventricular dysfunction is an umbrella term for both asymptomatic and symptomatic ventricular dysfunction. </p> </section> <section id="CD013015-sec-0069"> <h5 class="title">Clinical and methodological heterogeneity</h5> <p>We recognise that there is clinical and methodological heterogeneity between the included studies, and we carefully considered the appropriateness of pooling results. First, the duration of follow‐up varied from two years in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> to mean 4.3 years in <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>. Second, there were important differences in the inclusion criteria of the studies: <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> recruited only patients with type 2 diabetes and elevated NT‐proBNP, and <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> recruited a heterogeneous cohort of patients with various cardiovascular risk factors. <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> did not impose a threshold on NP level for inclusion in the study; therefore the control and intervention arms were heterogeneous for high‐ and low‐risk patients as classified by NP level. The components of the interventions also differed. <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> used a multi‐dimensional intervention, and <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> focused solely on optimisation of drug therapy. </p> <p>We acknowledge these important differences between studies, and we tried to explore the effects of these differences when possible. We assessed statistical heterogeneity visually and by using the I² statistic. We did not identify any statistical heterogeneity in any of our outcomes (I² = 0 for all). We did not have sufficient data to perform subgroup analyses for factors such as diabetes or duration of follow‐up; however, we hope that in future updates of this review, we will find sufficient data to explore these factors. </p> <p>We were able to perform subgroup analysis for the primary outcome cardiovascular hospitalisation in those with (1) BNP &lt; 50 pg/mL/NT‐proBNP &lt; 125 pg/mL and (2) BNP ≥ 50 pg/mL/NT‐proBNP ≥ 125 pg/mL (post hoc modification; see <a href="#CD013015-sec-0112">Differences between protocol and review</a>). The results of this analysis show that there was no significant difference in the effect estimate between subgroups. In view of these factors, we decided to pool results from both studies when possible. However, the findings of this review should be interpreted with caution due to the potential for clinical and methodological heterogeneity between studies. </p> </section> </section> <section id="CD013015-sec-0070"> <h4 class="title">Excluded studies</h4> <p>We have included 15 studies (19 references) in the <a href="./references#CD013015-sec-0115" title="">Characteristics of excluded studies</a> table. We excluded 10 of these studies (14 references) as the participants had heart failure or ventricular dysfunction at baseline, two because the study was not designed as an RCT, one as trial outcomes did not match our prespecified primary and secondary outcomes, and one because the intervention did not meet our inclusion criteria. One study met our eligibility criteria for inclusion in the review (<a href="./references#CD013015-bbs2-0012" title="NCT00604006 . SCREEN‐HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study). https://clinicaltrials.gov/ct2/show/study/NCT00604006 (first received 29 January 2008). ">NCT00604006</a>). However, we contacted the study author on 20 August 2019 to request data and were informed that no data were available. Therefore, we excluded the study. We excluded three more studies as they were duplicate reports of the same study. </p> <section id="CD013015-sec-0071"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing trials that met our inclusion criteria (<a href="./references#CD013015-bbs2-0018" title="DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . NT proBNP ‐ an important decision factor in preventing heart failure. European Journal of Clinical Investigation2015;2:6. DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. European Journal of Heart Failure2015;17:420‐31. DimitriuI , RaileanuM , AndreiC , SinescuC . NTproBNP ‐ an important decision factor in preventing heart failure. Proceedings of the 49th Annual Society Meeting of the European Society for Clinical Investigation. 2015:147‐51. DimitriuI , RaileanuM , CalinC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. Journal of Hypertension2015;33:e461‐2. DimitriuI , VoiculescuD , LacraruA , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in diabetic patients. European Journal of Clinical Investigation2017;47(Suppl 1):100. DimitriuI , VoiculescuD , RaileanuM , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in hypertensive patients. European Journal of Heart Failure2016;18(Suppl 1):249. DimitriuI , VoiculescuD , SinescuC . NTproBNP in patients with hypertension to prevent heart failure. European Journal of Clinical Investigation2016;1:15‐6. DimitriuI , Voiculescu , LacraruA , SinescuC . NT pro BNP ‐ a decision factor in preventing heart failure in diabetic patients. European Journal of Heart Failure2017;9(Suppl 1):408. Dimitriu I. Preventing heart failure using medical intervention guided by NTproBNP. Preventing heart failure using medical intervention guided by NTproBNP. Journal of Economic Computation and Economic Cybernetics Studies and Research2015;1:228‐36. ">Dimitriu 2015</a>; <a href="./references#CD013015-bbs2-0019" title="NCT02817360. NT‐proBNP selected prevention of cardiac events in diabetic patients. clinicaltrials.gov/ct2/show/NCT02817360?term=PONTIAC&amp;rank=2 (first posted 29 June 2016). ">Huelsmann 2016</a>). Details are shown in <a href="./references#CD013015-sec-0116" title="">Characteristics of ongoing studies</a>. Recruitment is ongoing for both trials. No data are available yet for <a href="./references#CD013015-bbs2-0019" title="NCT02817360. NT‐proBNP selected prevention of cardiac events in diabetic patients. clinicaltrials.gov/ct2/show/NCT02817360?term=PONTIAC&amp;rank=2 (first posted 29 June 2016). ">Huelsmann 2016</a>, and partial outcome data are available for <a href="./references#CD013015-bbs2-0018" title="DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . NT proBNP ‐ an important decision factor in preventing heart failure. European Journal of Clinical Investigation2015;2:6. DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. European Journal of Heart Failure2015;17:420‐31. DimitriuI , RaileanuM , AndreiC , SinescuC . NTproBNP ‐ an important decision factor in preventing heart failure. Proceedings of the 49th Annual Society Meeting of the European Society for Clinical Investigation. 2015:147‐51. DimitriuI , RaileanuM , CalinC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. Journal of Hypertension2015;33:e461‐2. DimitriuI , VoiculescuD , LacraruA , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in diabetic patients. European Journal of Clinical Investigation2017;47(Suppl 1):100. DimitriuI , VoiculescuD , RaileanuM , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in hypertensive patients. European Journal of Heart Failure2016;18(Suppl 1):249. DimitriuI , VoiculescuD , SinescuC . NTproBNP in patients with hypertension to prevent heart failure. European Journal of Clinical Investigation2016;1:15‐6. DimitriuI , Voiculescu , LacraruA , SinescuC . NT pro BNP ‐ a decision factor in preventing heart failure in diabetic patients. European Journal of Heart Failure2017;9(Suppl 1):408. Dimitriu I. Preventing heart failure using medical intervention guided by NTproBNP. Preventing heart failure using medical intervention guided by NTproBNP. Journal of Economic Computation and Economic Cybernetics Studies and Research2015;1:228‐36. ">Dimitriu 2015</a>. </p> </section> </section> </section> <section id="CD013015-sec-0072"> <h3 class="title">Risk of bias in included studies</h3> <p>We have detailed the risk of bias assessments in the <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012721.pub2/references#CD012721-sec2-0019" target="_blank">Characteristics of included studies</a> tables, and we have summarised these in the text below and in <a href="#CD013015-fig-0002">Figure 2</a> and <a href="#CD013015-fig-0003">Figure 3</a>. Assessment of risk of bias was based on both published and unpublished data. </p> <div class="figure" id="CD013015-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013015-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013015-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013015-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013015-sec-0073"> <h4 class="title">Allocation</h4> <p>We judged both studies to be at low risk for selection bias, as the randomisation sequence was computer‐generated (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Both studies clearly stated that the study was randomised, and one provided in the report sufficient details on the method of randomisation applied (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). For the second study, we obtained details on the method of randomisation through personal contact with the study author (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>). </p> <p>Allocation concealment was appropriate in both studies, and we judged risk of bias to be low (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Neither study reported allocation concealment in sufficient detail in the published report. We obtained information on allocation concealment through personal contact with study authors. </p> </section> <section id="CD013015-sec-0074"> <h4 class="title">Blinding</h4> <p>Blinding of participants and personnel (i.e. those delivering the intervention) to treatment allocation was not feasible due to the nature of the interventions. We determined that objective outcomes such as cardiovascular mortality, all‐cause mortality, ventricular dysfunction (echocardiographer and cardiologist reviewing end of study echo were blinded, and a clear definition of ventricular dysfunction was provided), and change in NP level at the end of follow‐up (laboratory measured parameter) were likely to be at low risk of performance bias in both studies, when included (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Subjective outcomes (cardiovascular hospitalisation and all‐cause hospitalisation) were likely to be at high risk of performance bias in both studies (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). </p> <p>We judged detection bias to be at low risk in both studies; outcome assessors were blinded to treatment allocation (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). </p> </section> <section id="CD013015-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <p>We judged one study to be at low risk of bias for incomplete outcome data (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>), and we determined that the second was at unclear risk of bias (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Both studies reported attrition by intervention arm, and one study provided detailed reasons for withdrawal (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> reported similar attrition between arms (13% in the control group and 9% in the intervention group). In <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, overall attrition (withdrawal and loss to follow‐up) was 23.2% in the intervention group and 29.7% in the control group. Given the longer mean duration of the study (4.2 years), the attrition rate is considered reasonable. </p> <p>In <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, withdrawal was slightly higher in the control group than in the intervention group (19% vs 13%). However, detailed reasons for patient withdrawal were provided, and it is clear that the differential withdrawal rate was unrelated to study outcomes of interest; therefore this is unlikely to have biased the results. </p> <p><a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> performed an intention‐to‐treat (ITT) analysis to account for missing data for the following outcomes: cardiovascular hospitalisation (multiple imputation using chained equations), ventricular dysfunction, and change in NP level at the end of follow‐up (last observation carried forward used for both). With regard to the outcomes all‐cause hospitalisation and all‐cause mortality, participants who were lost to follow‐up or who did not provide at least one year of data were excluded from the analysis. As this study contributed most of the data for these outcomes, we judged these outcomes to be at overall high risk of attrition bias. </p> <p><a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> did not perform an ITT analysis. However, participants who withdrew agreed to be followed‐up for the outcomes all‐cause hospitalisation, cardiovascular hospitalisation, and death (information was obtained from mortality data and hospital files), so missing data was not an issue for these outcomes; therefore risk of attrition bias was low. For the outcome change in NP level at end of follow‐up, patients who withdrew from the study were excluded from the analysis. </p> </section> <section id="CD013015-sec-0076"> <h4 class="title">Selective reporting</h4> <p>Both studies were preregistered at appropriate clinical trials registries, where predefined outcomes of interest were listed (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Both studies were considered at high risk for reporting bias. </p> <p><a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> reported on all planned outcomes specified in the clinical trials registry entry; however, additional secondary outcomes listed in the paper were not prespecified in the clinical trials registry (all‐cause hospitalisation, unplanned cardiovascular hospitalisation or death, and heart failure hospitalisation). </p> <p><a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> has not yet reported on some of the secondary outcomes outlined in the study protocol (unpublished protocol obtained from study authors): (1) relative effects of intervention in prespecified subgroups: above and below median age, male/female, hypertension, diabetes, vascular disease, structural CVD, obesity; (2) relative effects of the intervention on Health and Lifestyle questionnaire; and (3) evaluation of clinical, demographic, biochemical, pharmacological, genomic, proteomic, and metabolomic determinants of natriuretic peptides. Through direct communication with study authors, we confirmed that these outcomes have not yet been reported. </p> </section> <section id="CD013015-sec-0077"> <h4 class="title">Other potential sources of bias</h4> <p>We did not identify any other potential sources of bias; therefore we judged risk of bias for this domain to be low. </p> </section> </section> <section id="CD013015-sec-0078"> <h3 class="title" id="CD013015-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD013015-tbl-0001"><b>Summary of findings for the main comparison</b> Natriuretic peptide‐guided treatment compared to standard care for the prevention of cardiovascular events in patients without heart failure</a> </p> <section id="CD013015-sec-0079"> <h4 class="title">Cardiovascular mortality</h4> <p>One study with 300 participants reported cardiac mortality (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>); therefore we were unable to perform meta‐analysis. As data for cardiovascular mortality were not available, we used event numbers for cardiac mortality. Event numbers were very low (one death in the intervention group and three in the control group), and there was uncertainty about effects of the intervention (risk ratio (RR) 0.33, 95% confidence interval (CI) 0.04 to 3.17; low‐quality evidence; <a href="./references#CD013015-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD013015-sec-0080"> <h4 class="title">Cardiovascular hospitalisation</h4> <p>Two studies with 1674 participants reported on cardiovascular hospitalisation (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Study authors reported 135 cardiovascular hospitalisations in the control group and 72 in the intervention group (16% vs 9%). Pooled results based on a fixed‐effect model favoured the intervention group (RR 0.52, 95% CI 0.40 to 0.68; I² = 0%; moderate‐quality evidence; <a href="./references#CD013015-fig-0005" title="">Analysis 1.2</a>). Thus, moderate‐quality evidence suggests that NP‐guided treatment probably reduces the risk of cardiovascular hospitalisation. </p> </section> <section id="CD013015-sec-0081"> <h4 class="title">All‐cause mortality</h4> <p>Two studies with 1354 participants reported on all‐cause mortality (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). In all, 45 deaths due to any reason were reported in the control group (7%) and 41 in the intervention group (6%). Pooled evidence, based on a fixed‐effect model, favoured NP‐guided treatment, but overall, the evidence showed uncertainty (RR 0.90, 95% CI 0.60 to 1.35; I² = 0%; low‐quality evidence; <a href="./references#CD013015-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD013015-sec-0082"> <h4 class="title">All‐cause hospitalisation</h4> <p>Two studies with 1354 participants reported on all‐cause hospitalisation (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Study authors reported 404 hospitalisations for any reason in the control group (60%) and 341 in the intervention group (50%). The pooled result based on a fixed‐effect model favoured the intervention (RR 0.83, 95% CI 0.75 to 0.92; I² = 0%; moderate‐quality evidence; <a href="./references#CD013015-fig-0008" title="">Analysis 1.5</a>). Thus, moderate‐quality evidence suggests that NP‐guided treatment probably reduces the risk of all‐cause hospitalisation. </p> </section> <section id="CD013015-sec-0083"> <h4 class="title">Ventricular dysfunction</h4> <p>One study with 1374 participants reported on ventricular dysfunction, defined as heart failure or left ventricular dysfunction (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Fifty‐nine participants in the control group (9%) and 37 in the intervention group (5%) developed ventricular dysfunction. Results show a reduction in the risk of developing ventricular dysfunction with NP‐guided treatment compared to standard care (RR 0.61, 95% CI 0.41 to 0.91; high‐quality evidence; <a href="./references#CD013015-fig-0009" title="">Analysis 1.6</a>). </p> </section> <section id="CD013015-sec-0084"> <h4 class="title">Change in NP level at the end of follow‐up</h4> <p>Both studies reported change in NP level (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). For <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, we calculated change in BNP from baseline to follow‐up (mean 4.2 years). <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> provided median NT‐proBNP values at baseline and after one year (follow‐up for all other outcomes was two years, but patients attended study visits for only 12 months). Given that each study used a different biomarker and that NP level was measured at different time points, it was not appropriate to perform meta‐analysis on this outcome. Furthermore, data from <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> were reported as median and interquartile range (IQR), indicating that the data were skewed. </p> <p>NP levels increased in both groups from baseline to time of measurement. This is consistent with previous research demonstrating that NP level increases with age (<a href="./references#CD013015-bbs2-0080" title="RedfieldM , RodehefferR , JacobsenS , MahoneyD , BaileyK , BurnettJ . Plasma brain natriuretic peptide concentration: impact of age and gender. Journal of the American College of Cardiology2002;40(5):976‐82. ">Redfield 2002</a>; <a href="./references#CD013015-bbs2-0093" title="WangT , LarsonM , LevyD , LeipE , BenjaminE , WilsonP , et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. American Journal of Cardiology2002;90(3):254‐8. ">Wang 2002</a>). In <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, the mean difference in NP level from baseline to follow‐up was slightly lower in the intervention group than in the control group (mean difference (MD) from baseline to follow‐up: control arm 9.52 pg/mL, intervention arm 5.46 pg/mL). However, the evidence shows uncertainty for the effects of NP‐guided treatment on NP level at the end of follow‐up (MD between groups: 4.06 pg/mL, 95% CI ‐15.07 pg/mL to 6.95 pg/mL; 1 study; 1374 participants; moderate‐quality evidence; <a href="./references#CD013015-fig-0010" title="">Analysis 1.7</a>). Results show no significant differences between groups in change in BNP from baseline to follow‐up (P = 0.47). </p> <p>For <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>, as the data were provided as median and IQR, we were unable to calculate the mean difference between groups. From the median values presented, we noted no significant change in NT‐proBNP concentration between groups after one year of treatment (NT‐proBNP at baseline (presented as median value): control group 266 pg/mL, IQR 181 to 402 pg/mL; intervention group 235 pg/mL, IQR 169 to 343 pg/mL; NT‐proBNP after 12 months (presented as median value): control group 264 pg/mL, IQR 167 to 394 pg/mL; intervention group 248 pg/mL, IQR 169 to 433 pg/mL). </p> <p>It should be noted that currently no consensus has been reached on what should be considered a clinically significant change in NP level among patients without heart failure. Preanalytical factors and analytical and biological variability (which increases with time) contribute to the total intraindividual variability in NP level (<a href="./references#CD013015-bbs2-0034" title="FraserC . Biological variation: from principles to practice. Biological Variation: From Principles to Practice. Washington, DC: AACC Press, 2006:67‐90. ">Fraser 2006</a>). Research conducted in heart failure patients suggests that changes in NT‐proBNP and BNP of 50% and 66%, respectively, over the course of one week are likely to signal a clinically significant change in patient status (<a href="./references#CD013015-bbs2-0070" title="O'HanlonR , O'SheaP , LedwidgeM , O'LoughlinC , LangeS , ConlonC , et al. The biologic variability of B‐type natriuretic peptide and N‐terminal pro‐B‐type natriuretic peptide in stable heart failure patients. Journal of Cardiac Failure2007;13:150‐5. ">O'Hanlon 2007</a>), and an earlier small study suggested that in heart failure patients, a change in BNP/NT‐proBNP exceeding 30% is clinically meaningful (<a href="./references#CD013015-bbs2-0022" title="BettencourtP , AzevedoA , PimentaJ , FriõesF , FerreiraS , FerreiraA . N‐terminal pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation2004;110:2168–74. ">Bettencourt 2004</a>). </p> </section> <section id="CD013015-sec-0085"> <h4 class="title">Subgroup analysis</h4> <p>With the exception of NP level at baseline, it was not possible to explore subgroups within study populations as per protocol. In the review protocol, we planned to perform subgroup analysis according to those with (1) BNP 35 pg/mL to 100 pg/mL or NT‐proBNP 125 pg/mL to 300 pg/mL, and (2) BNP ≥ 100 pg/mL and NT‐proBNP ≥ 300 pg/mL. However, this was changed post hoc in light of the thresholds recommended by more recent guidelines (<a href="./references#CD013015-bbs2-0032" title="EzekowitzJA , O'MearaE , McDonaldMA , AbramsH , ChanM , DucharmeA , et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology2017;33(11):1342‐433. ">Ezekowitz 2017</a>) (see <a href="#CD013015-sec-0112">Differences between protocol and review</a>). We performed subgroup analysis for the following values: (1) BNP &lt; 50 pg/mL and NT‐proBNP &lt; 125 pg/mL, and (2) BNP ≥ 50 pg/mL and NT‐proBNP ≥ 125 pg/mL. </p> <p>Subgroup analysis by NP level for the primary outcome cardiovascular hospitalisation shows that NP‐guided treatment reduced the risk of cardiovascular hospitalisation in both subgroups. Point estimates were similar in both subgroups and confidence intervals overlapped (BNP &lt; 50 pg/mL and NT‐proBNP &lt; 125 pg/mL: RR 0.55, 95% CI 0.32 to 0.95; 1 study; 876 participants; BNP ≥ 50 pg/mL and NT‐proBNP ≥ 125 pg/mL: RR 0.49, 95% CI 0.36 to 0.65; 2 studies; 798 participants; <a href="./references#CD013015-fig-0006" title="">Analysis 1.3</a>). The subgroup test for differences was non‐significant (P = 0.66). </p> <p>We did not have sufficient data to perform subgroup analysis of NP level for the other pooled outcomes (all‐cause hospitalisation and all‐cause mortality). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013015-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013015-sec-0086">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013015-sec-0148">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013015-sec-0086"></div> <section id="CD013015-sec-0087"> <h3 class="title" id="CD013015-sec-0087">Summary of main results</h3> <p>We included in our review three reports of two trials (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). We identified two ongoing trials with treatment arms that include interventions assessed in this review (<a href="./references#CD013015-bbs2-0018" title="DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . NT proBNP ‐ an important decision factor in preventing heart failure. European Journal of Clinical Investigation2015;2:6. DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. European Journal of Heart Failure2015;17:420‐31. DimitriuI , RaileanuM , AndreiC , SinescuC . NTproBNP ‐ an important decision factor in preventing heart failure. Proceedings of the 49th Annual Society Meeting of the European Society for Clinical Investigation. 2015:147‐51. DimitriuI , RaileanuM , CalinC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. Journal of Hypertension2015;33:e461‐2. DimitriuI , VoiculescuD , LacraruA , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in diabetic patients. European Journal of Clinical Investigation2017;47(Suppl 1):100. DimitriuI , VoiculescuD , RaileanuM , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in hypertensive patients. European Journal of Heart Failure2016;18(Suppl 1):249. DimitriuI , VoiculescuD , SinescuC . NTproBNP in patients with hypertension to prevent heart failure. European Journal of Clinical Investigation2016;1:15‐6. DimitriuI , Voiculescu , LacraruA , SinescuC . NT pro BNP ‐ a decision factor in preventing heart failure in diabetic patients. European Journal of Heart Failure2017;9(Suppl 1):408. Dimitriu I. Preventing heart failure using medical intervention guided by NTproBNP. Preventing heart failure using medical intervention guided by NTproBNP. Journal of Economic Computation and Economic Cybernetics Studies and Research2015;1:228‐36. ">Dimitriu 2015</a>; <a href="./references#CD013015-bbs2-0019" title="NCT02817360. NT‐proBNP selected prevention of cardiac events in diabetic patients. clinicaltrials.gov/ct2/show/NCT02817360?term=PONTIAC&amp;rank=2 (first posted 29 June 2016). ">Huelsmann 2016</a>). We performed pooled analysis on the outcomes cardiovascular hospitalisation, all‐cause hospitalisation, and all‐cause mortality. Single studies included the outcomes ventricular dysfunction and cardiovascular mortality; thus we could not perform pooled analyses. </p> <p>Moderate‐quality evidence indicates that natriuretic peptide (NP)‐guided treatment probably reduces the risk of cardiovascular hospitalisation (48% risk reduction) and all‐cause hospitalisation (17% risk reduction) in those with risk factors for cardiovascular disease (CVD). High‐quality evidence shows a reduction in the risk of developing ventricular dysfunction with NP‐guided treatment compared to standard care; however this evidence was derived from a single study. Due to wide confidence intervals, there was uncertainty around the estimate of effects for the outcomes cardiovascular mortality, all‐cause mortality, and change in NP level at the end of follow‐up. Therefore, we cannot draw clear conclusions as to the effects of NP‐guided treatment on these outcomes. </p> <p>Subgroup analysis by NP level at baseline shows that NP‐guided treatment reduces the risk of cardiovascular hospitalisation to a similar degree in both subgroups. This analysis also indicates that differences in patient characteristics according to NP level at baseline in each study did not introduce heterogeneity into our results (all participants in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> had NT‐proBNP &gt;125 pg/mL, and <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> did not impose a threshold on NP level for inclusion in the study). </p> <p>It must be noted that we identified clinical and methodological heterogeneity in the two included studies (<a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>; <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Although we did not identify any statistical heterogeneity in our pooled results, we were largely unable to explore possible sources of heterogeneity through subgroup analysis due to lack of data; therefore the results of this review should be interpreted with caution. </p> </section> <section id="CD013015-sec-0088"> <h3 class="title" id="CD013015-sec-0088">Overall completeness and applicability of evidence</h3> <p>The generalisability of this review was limited by the small number of studies identified for inclusion. However, although only two studies met the criteria for our review, our conclusions for all outcomes except cardiovascular mortality (data from one study with 300 participants; <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>) are based on analysis of between 1354 and 1674 analytical units, which contributes to the robustness of our findings. </p> <p>Both studies were conducted at large urban centres in high‐income countries in Europe, and most participants were Caucasian. Therefore, our findings may not be generalisable to other ethnicities and income settings. In both studies, the intervention was delivered through a specialist cardiology outpatient clinic by a team of speciality staff (note that in <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>, intervention group patients with BNP &lt; 50 pg/mL were cared for by their primary care physician). It is possible that results observed in the two studies would not be reproducible in other, less than ideal healthcare settings, such as primary care alone without specialist support. </p> <p>Despite the small number of studies included, we were able to obtain data on all outcomes prespecified in the review protocol, and we were able to perform meta‐analysis on three of the six outcomes. Although we were able to obtain data on the outcome measures cardiovascular mortality, all‐cause mortality, and all‐cause hospitalisation, these were not planned outcomes of the included studies (all‐cause hospitalisation was a planned secondary outcome in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a>, but not in <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Neither of the studies included in our review were powered to detect differences in mortality between control and intervention groups; this, combined with the short duration of follow‐up, accounts for the small event numbers and imprecision seen in effect estimates for the outcomes cardiovascular mortality and all‐cause mortality. Thus, adequately powered studies with longer duration of follow‐up are needed to accurately assess the effects of NP‐guided treatment on mortality. </p> <p>Evidence on the effects of NP‐guided treatment on the outcome ventricular dysfunction is available from a single study (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>). Given the low event rate, the absolute risk reduction was small and the generalisability of this potential benefit is limited. </p> <p>The comparator in the studies included in this review is 'standard care', which we defined as local guideline‐based care, including modification of pharmacological, educational, and lifestyle interventions, while not taking into account the participant’s NP level. It is important to note that standard care may vary considerably from setting to setting, depending on factors such as resource limitations, physician characteristics, and local guidelines. For some physicians, standard care may simply encompass the prescribing of drug therapy, but others may take a more holistic approach, routinely incorporating advice about lifestyle factors and medication adherence behaviours. Therefore, it is possible that the relative effects of the intervention may vary depending on the setting and the definition of standard care adopted by physicians. </p> <p>We intended to perform subgroup analysis to determine whether several factors including age, gender, diabetes mellitus, obesity, atrial fibrillation versus non‐atrial fibrillation, valvular heart disease versus non‐valvular heart disease, ischaemic heart failure versus non‐ischaemic heart failure, NP level at baseline, or renal function had any impact on the primary outcome. However, due to the paucity of data, we were unable to perform our planned subgroup analyses, with the exception of NP level at baseline. This information would be useful for investigating whether all people with cardiovascular risk factors derive a similar benefit from NP‐guided treatment, or whether efforts should be targeted towards specific subpopulations. For future updates of this review, we hope that more detailed subgroup data will be available, so we can provide a more robust analysis. </p> <p>Neither of the studies included explicitly reported on the safety of the intervention or provided the number of adverse events, although <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> did note that there were no hospitalisations for adverse events. </p> <p>We identified two ongoing trials (<a href="./references#CD013015-bbs2-0018" title="DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . NT proBNP ‐ an important decision factor in preventing heart failure. European Journal of Clinical Investigation2015;2:6. DimitriuI , RaileanuM , AndreiC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. European Journal of Heart Failure2015;17:420‐31. DimitriuI , RaileanuM , AndreiC , SinescuC . NTproBNP ‐ an important decision factor in preventing heart failure. Proceedings of the 49th Annual Society Meeting of the European Society for Clinical Investigation. 2015:147‐51. DimitriuI , RaileanuM , CalinC , DorobantuM , SinescuC . Preventing heart failure using medical intervention guided by NTproBNP. Journal of Hypertension2015;33:e461‐2. DimitriuI , VoiculescuD , LacraruA , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in diabetic patients. European Journal of Clinical Investigation2017;47(Suppl 1):100. DimitriuI , VoiculescuD , RaileanuM , SinescuC . Role of NT proBNP in preventing left ventricular dysfunction in hypertensive patients. European Journal of Heart Failure2016;18(Suppl 1):249. DimitriuI , VoiculescuD , SinescuC . NTproBNP in patients with hypertension to prevent heart failure. European Journal of Clinical Investigation2016;1:15‐6. DimitriuI , Voiculescu , LacraruA , SinescuC . NT pro BNP ‐ a decision factor in preventing heart failure in diabetic patients. European Journal of Heart Failure2017;9(Suppl 1):408. Dimitriu I. Preventing heart failure using medical intervention guided by NTproBNP. Preventing heart failure using medical intervention guided by NTproBNP. Journal of Economic Computation and Economic Cybernetics Studies and Research2015;1:228‐36. ">Dimitriu 2015</a>; <a href="./references#CD013015-bbs2-0019" title="NCT02817360. NT‐proBNP selected prevention of cardiac events in diabetic patients. clinicaltrials.gov/ct2/show/NCT02817360?term=PONTIAC&amp;rank=2 (first posted 29 June 2016). ">Huelsmann 2016</a>). The results of these trials are likely to have an important impact on our confidence in the estimates of effect and may change the estimates relative to the current evidence base, given the number of participants and the estimated number of events. </p> </section> <section id="CD013015-sec-0089"> <h3 class="title" id="CD013015-sec-0089">Quality of the evidence</h3> <p>The quality of evidence for the outcomes included in this review ranged from low to high. Potential sources of bias identified included selective reporting, lack of blinding of participants and personnel for subjective outcomes, and attrition bias. </p> <p>We deemed the quality of evidence (GRADE; <a href="./full#CD013015-tbl-0001">summary of findings Table for the main comparison</a>) to be moderate for cardiovascular hospitalisation, all‐cause hospitalisation (both downgraded by one level due to high risk of performance bias), and change in NP level at the end of follow‐up (downgraded by one level due to imprecision of effect size; wide confidence interval consistent with the possibility of causing benefit and harm). High‐quality evidence from a single study suggests that the risk of developing ventricular dysfunction is reduced by NP‐guided treatment. Although only one study reported this outcome, we did not downgrade for indirectness, in view of the large sample size and the broad patient population included in this study. </p> <p>We judged the quality of evidence for cardiovascular mortality (single study) to be low due to serious concerns over substantial imprecision and small sample size; thus our confidence in the pooled result is low, and our estimate is likely to be affected by future research. We also considered the quality of evidence for the outcome all‐cause mortality (two studies) to be low due to concerns over imprecision and attrition bias. </p> <p>We judged imprecision by whether the 95% confidence interval (CI) included the null, and whether it included important benefits and harms. When the confidence interval of the overall effect included both no effect and potential harm, we downgraded the evidence. Thus, we downgraded the evidence for cardiovascular mortality, all‐cause mortality, and change in NP level at the end of follow‐up. We did not downgrade the quality of evidence for any outcome due to inconsistency as no statistical heterogeneity was identified, nor for indirectness. </p> <p>It is important to note that for the outcome cardiovascular hospitalisation, we noted slight heterogeneity in the definitions used by study authors. <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> defined cardiovascular hospitalisation as any unplanned hospitalisation based on a cardiac (e.g. arrhythmia) or other macrovascular event (e.g. stroke, coronary artery disease, peripheral arterial disease). <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> defined cardiovascular hospitalisation as emergency hospitalisation for any of the following major adverse cardiovascular events: arrhythmia, transient ischaemic attack, stroke, myocardial infarction, peripheral or pulmonary thrombosis/embolus, or heart failure. Although <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> used a slightly broader definition, we were satisfied that the two definitions were similar enough to permit pooling of the results. </p> <p>We acknowledge that there are several caveats in the interpretation of our results. First, none of the studies included in this review were designed to evaluate the effects of NP‐guided treatment on mortality; hence event numbers were low and there was significant imprecision in the estimates of effect. Second, our outcome results were dominated by a single study (<a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a>), which contributed 82% of the data to our pooled analyses. Third, we recognise that there is methodological and clinical heterogeneity between the included studies, and we were unable to explore these sources of heterogeneity through subgroup analysis due to the paucity of data. We carefully considered the appropriateness of pooling the data. In view of the lack of statistical heterogeneity identified between studies, we made a decision to pool the studies for our analysis. We were also cognisant of the fact that our review addresses a broad question in a broad participant group; therefore the heterogeneity in our studies may reflect the 'real‐life' situation. Thus, even in view of the heterogeneity, meta‐analysis is still likely to be useful. However, it is important to note that our pooled results should be interpreted with caution due to the potential for clinical and methodological heterogeneity between studies. </p> </section> <section id="CD013015-sec-0090"> <h3 class="title" id="CD013015-sec-0090">Potential biases in the review process</h3> <p>Four of the review authors (ML, KMD, CW, JG) were involved in one of the included studies. These authors were not involved in the screening of articles, nor in assessing the risk of bias or grading the quality of included studies for this systematic review and meta‐analysis. </p> <p>We acknowledge the potential for publication bias in the systematic review. Although we did perform a thorough search with no date or language restrictions, there is inevitably the possibility that we may not have found relevant unpublished trials. However, we received excellent support from the Cochrane Heart Information Specialist, who assisted us in performing comprehensive and systematic database searches to minimise the risk of publication bias. In addition, we minimised study selection bias by assigning two review authors to independently review search results and to evaluate studies for inclusion against our predefined inclusion criteria. </p> <p>Due to lack of available data, we were unable to perform most of our planned subgroup analyses. It is unclear whether the additional data would have altered the overall findings of this review. </p> </section> <section id="CD013015-sec-0091"> <h3 class="title" id="CD013015-sec-0091">Agreements and disagreements with other studies or reviews</h3> <p>To the best of our knowledge, this is the first systematic review and meta‐analysis to examine the effects of NP‐guided treatment for prevention of cardiovascular events in patients without heart failure. Multiple systematic reviews and meta‐analyses ‐ <a href="./references#CD013015-bbs2-0020" title="BalionC , McKelvieR , Don‐WauchopeAC , SantaguidaPL , OremusM , KeshavarzH , et al. B‐type natriuretic peptide‐guided therapy: a systematic review. Heart Failure Review2014;19:553‐64. ">Balion 2014</a>; <a href="./references#CD013015-bbs2-0028" title="VecchisR , EspositoC , BiaseG , ArianoC , GiasiA , CioppaC . B‐type natriuretic peptide‐guided versus symptom‐guided therapy in outpatients with chronic heart failure: a systematic review with meta‐analysis. Journal of Cardiovascular Medicine2014;15(2):122‐34. ">De Vecchis 2014</a>; <a href="./references#CD013015-bbs2-0054" title="LiP , LuoY , ChenY . B‐type natriuretic peptide‐guided chronic heart failure therapy: a meta‐analysis of 11 randomised controlled trials. Heart, Lung and Circulation2013;22(1):852‐60. ">Li 2013</a>; <a href="./references#CD013015-bbs2-0077" title="PorapakkhamP , PorapakkhamP , ZimmetH , BillahB , KrumH . B‐type natriuretic peptide‐guided heart failure therapy: a meta‐analysis. Archives of Internal Medicine2010;170(6):507‐14. ">Porapakkham 2010</a>; <a href="./references#CD013015-bbs2-0085" title="SavareseG , TrimarcoB , DellegrottaglieS , PrastaroM , GambardellaF , RengoG , et al. Natriuretic peptide‐guided therapy in chronic heart failure: a meta‐analysis of 2,686 patients in 12 randomized trials. PLOS One2013;8(3):e96706. ">Savarese 2013</a>; <a href="./references#CD013015-bbs2-0092" title="TroughtonRW , FramptonCM , Brunner‐La RoccaHP , PfistererM , EurlingsLWM , ErntellH , et al. Effect of B‐type natriuretic peptide‐guided treatment of chronic heart failure on total mortality and hospitalisation: an individual patient meta‐analysis. European Heart Journal2014;35:1559‐67. ">Troughton 2014</a> ‐ and one Cochrane Review ‐ <a href="./references#CD013015-bbs2-0062" title="McLellanJ , HeneghanCJ , PereraR , ClementsAM , GlasziouPP , KearleyKE , et al. B‐type natriuretic peptide‐guided treatment for heart failure. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD008966.pub2] ">McLellan 2016</a> ‐ have explored the effects of NP‐guided treatment for patients with heart failure. However, due to the different patient populations included, it is not appropriate to make comparisons with these reviews. </p> <p>A community cohort study by AbouEzzeddine and colleagues mirrors the findings of our meta‐analysis (<a href="./references#CD013015-bbs2-0003" title="AbouEzzeddineOF , McKiePM , ScottCG , RodehefferRJ , ChenHH , Michael FelkerG , et al. Biomarker‐based risk prediction in the community. European Journal of Heart Failure2016;18(11):1342‐50. ">AbouEzzedine 2016</a>). These study authors identified a ‘STOP‐HF‐like’ cohort of 1576 participants without heart failure or systolic dysfunction from the Olmsted County population who had one or more cardiovascular risk factors (hypertension, hyperlipidaemia, obesity, vascular disease, diabetes, atrial fibrillation, or valve disease). Participants underwent screening for multiple biomarkers, including BNP and NT‐proBNP, and received a ‘STOP‐HF‐type’ preventive intervention over a four‐year period. </p> <p>Review authors provided a theoretical model to evaluate whether biomarker‐guided management can prevent development of heart failure or occurrence of major adverse cardiovascular events (MACE) in a community sample. AbouEzzeddine and colleagues applied the effect estimates obtained from the biomarker screening strategy employed in STOP‐HF to demonstrate the efficacy of applying this strategy outside of the rigorously controlled randomised controlled trial (RCT) setting (<a href="./references#CD013015-bbs2-0063" title="MeijersWC , deBoerRA , HoJE . Biomarkers to identify and prevent new‐onset heart failure in the community. European Journal of Heart Failure2016;18(11):1351‐2. ">Meijers 2016</a>). Biomarker screening followed by a preventive intervention achieved a reduction of 19% and 25% when screened with N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and brain natriuretic peptide (BNP), respectively, in the biomarker‐positive population. However, this analysis assumed no change in MACE incidence in the population that was biomarker‐negative (<a href="./references#CD013015-bbs2-0003" title="AbouEzzeddineOF , McKiePM , ScottCG , RodehefferRJ , ChenHH , Michael FelkerG , et al. Biomarker‐based risk prediction in the community. European Journal of Heart Failure2016;18(11):1342‐50. ">AbouEzzedine 2016</a>). </p> <p>In our meta‐analysis, the intervention was associated with a 48% reduction in the risk of hospitalisation due to cardiovascular causes. The difference in observed risk estimates may be due to disparities in the design of the intervention delivered to patients. In the study by AbouEzzeddine et al, the intervention consisted of a single agent or strategy for cardiovascular prevention. By comparison, participants in <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> and <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> received a specialist intervention with thorough evaluation and follow‐up. This, along with the ideal conditions of the RCT environment, may account for the stronger effect estimates observed in these studies. </p> <p>Both <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> and <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013</a> are included in the 2017 Canadian Cardiovascular Society Heart Failure Management Guidelines (<a href="./references#CD013015-bbs2-0032" title="EzekowitzJA , O'MearaE , McDonaldMA , AbramsH , ChanM , DucharmeA , et al. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. Canadian Journal of Cardiology2017;33(11):1342‐433. ">Ezekowitz 2017</a>), which recommend that among individuals with risk factors for the development of heart failure, those with BNP &gt; 50 pg/mL or NT‐proBNP &gt; 125 pg/mL should undergo imaging and consultation with a specialist, followed by optimisation of neurohormonal blocking therapy and lifestyle interventions. </p> <p>US guidelines also recommend NP screening for patients with risk factors for developing heart failure, with subsequent optimisation of guideline‐directed management and therapy by a cardiovascular specialist, to prevent the development of left ventricular dysfunction (systolic or diastolic) or new‐onset heart failure (<a href="./references#CD013015-bbs2-0100" title="YancyCW , JessupM , BozkurtB , ButlerJ , CaseyDE , ColvinMM , et al. ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation2017;136:137‐61. ">Yancy 2017</a>). In common with our own recommendations, these guidelines recommend further studies to examine the effects of NP screening and subsequent NP‐guided care on mortality. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013015-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA flow diagram." data-id="CD013015-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013015-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013015-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 1 Cardiovascular mortality (as defined by trialists)." data-id="CD013015-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 1 Cardiovascular mortality (as defined by trialists). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 2 Cardiovascular hospitalisation (as defined by trialists)." data-id="CD013015-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 2 Cardiovascular hospitalisation (as defined by trialists). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 3 Cardiovascular hospitalisation (as defined by trialists) by natriuretic peptide level." data-id="CD013015-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 3 Cardiovascular hospitalisation (as defined by trialists) by natriuretic peptide level. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 4 All‐cause mortality." data-id="CD013015-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 4 All‐cause mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 5 All‐cause hospitalisation (all occurrences)." data-id="CD013015-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 5 All‐cause hospitalisation (all occurrences). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 6 Ventricular dysfunction (as defined by trialists)." data-id="CD013015-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 6 Ventricular dysfunction (as defined by trialists). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013015-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/urn:x-wiley:14651858:media:CD013015:CD013015-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_t/tCD013015-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 7 Change in NP level at the end of follow‐up." data-id="CD013015-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Natriuretic peptide‐guided treatment versus standard care, Outcome 7 Change in NP level at the end of follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/media/CDSR/CD013015/image_n/nCD013015-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013015-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Natriuretic peptide‐guided treatment compared to standard care for the prevention of cardiovascular events in patients without heart failure</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Natriuretic peptide‐guided treatment compared to standard care for the prevention of cardiovascular events in patients without heart failure</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients without heart failure<br/> <b>Setting:</b> any<br/> <b>Intervention:</b> natriuretic peptide‐guided treatment<br/> <b>Comparison:</b> standard care </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with standard care</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with natriuretic peptide‐guided treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular mortality</p> <p>Follow‐up: 2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.33<br/> (0.04 to 3.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular deaths not available, so cardiac deaths used</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 1000<br/> (1 to 63) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Cardiovascular hospitalisation (as defined by trialists)</p> <p>Follow‐up range:</p> <p>2 years to mean 4.2 years</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.52<br/> (0.40 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1674<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>163 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85 per 1000<br/> (65 to 111) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause mortality<br/> Follow‐up: range 2 years to mean 4.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.90<br/> (0.60 to 1.35) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1354<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>60 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>54 per 1000<br/> (36 to 81) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>All‐cause hospitalisation (all occurrences)<br/> Follow‐up: range 2 years to mean 4.3 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/> (0.75 to 0.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1354<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>601 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>499 per 1000<br/> (457 to 553) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ventricular dysfunction (as defined by trialists)<br/> Assessed with Doppler echocardiography<br/> Follow‐up: mean 4.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.61<br/> (0.41 to 0.91) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1374<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/> HIGH<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Ventricular dysfunction was defined by trialists as left ventricular dysfunction and heart failure. Left ventricular dysfunction (LVD) included all patients with asymptomatic left ventricular systolic dysfunction (LVSD) and/or asymptomatic left ventricular diastolic dysfunction (LVDD). Heart failure included all patients with LVD (LVSD and/or LVDD) and with symptoms of heart failure requiring emergency admission to hospital </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/> (36 to 79) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in NP level at the end of follow‐up<br/> Follow‐up: mean 4.2 years </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in NP level at the end of follow‐up was 9.52 pg/mL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 4.06 pg/mL higher<br/> (15.07 lower to 6.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1374<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>These data come from <a href="./references#CD013015-bbs2-0002" title="NCT00921960. St Vincent's Screening TO Prevent Heart Failure Study (STOP‐HF). clinicaltrials.gov/ct2/show/NCT00921960?term=st+vincents+screening+to+prevent+heart+failure&amp;rank=1 (first posted 17 June 2009). LedwidgeM , McDonaldK . St Vincent's Screening TO Prevent Heart Failure (STOP‐HF) study using natriuretic peptides to identify and prevent progression of left ventricular dysfunction in community based, asymptomatic, at‐risk individuals: a prospective randomised controlled trial of natriuretic peptide based screening and collaborative care to reduce the prevalence of left ventricular dysfunction and heart failure (as supplied 18/09/2018). Data on file. LedwidgeM , O'ConnellE , GallagherJ , TilsonL , JamesS , VoonV , et al. Cost‐effectiveness of natriuretic peptide‐based screening and collaborative care: a report from the STOP‐HF (St Vincent's Screening TO Prevent Heart Failure) study. European Journal of Heart Failure2015;17(7):672‐9. LedwigeM , GallagherJ , ConlonC , TallonE , O'ConnellE , DawkinsI , et al. Natriuretic peptide–based screening and collaborative care for heart failure: the STOP‐HF randomized trial. Journal of the American Medical Association2013;310 (1):66‐74. ">Ledwidge 2013;</a> NP level was reported as BNP. <a href="./references#CD013015-bbs2-0001" title="NCT00562952. Nt‐proBNP Guided Primary Prevention of CV Events in Diabetic Patients (PONTIAC). clinicaltrials.gov/ct2/show/NCT00562952 (first posted 26 November 2007). HuelsmannM , NeuholdS , ReslM , StrunkG , BrathH , FrancesconiC , et al. PONTIAC (NT‐proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. Journal of the American College of Cardiology2013;62 (16):1365‐72. ">Huelsmann 2013</a> also reported change in NT‐proBNP after 1 year of treatment. However, these data were presented as median and interquartile range; therefore we could not calculate mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Imprecision: very wide 95% confidence interval, which includes the line of null effect and is consistent with the possibility of both important benefits and harms. The sample size is small. Downgraded by two levels. </p> <p><sup>b</sup>Risk of bias: both studies did not blind patients or personnel. Downgraded by one level. </p> <p><sup>c</sup>Imprecision: wide 95% confidence interval, which includes the line of null effect and is consistent with the possibility of important benefits and harms. Downgraded by one level. </p> <p><sup>d</sup>Risk of bias: downgraded by one level due to attrition bias as one study excluded from analysis patients who were lost to follow‐up and those who withdrew, who did not have at least one year of detailed follow‐up cost data. </p> <p><sup>e</sup>Risk of bias: echocardiographer and cardiologist reviewing end of study echo were blinded and diagnosis of ventricular dysfunction was based on clearly defined echocardiographic measures, which removed subjectivity in outcome assessment. Not downgraded. </p> <p><sup>f</sup>Imprecision: wide CIs that cross the line of no effect (zero) and include the possibility of the intervention causing both benefit and harm. Downgraded by one level. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Natriuretic peptide‐guided treatment compared to standard care for the prevention of cardiovascular events in patients without heart failure</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/full#CD013015-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013015-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Natriuretic peptide‐guided treatment versus standard care</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Cardiovascular mortality (as defined by trialists) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular hospitalisation (as defined by trialists) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.40, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular hospitalisation (as defined by trialists) by natriuretic peptide level <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.38, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 BNP &lt; 50 pg/mL and NT‐proBNP &lt; 125 pg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.32, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 BNP &gt; 50 pg/mL and NT‐proBNP &gt; 125 pg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.36, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.60, 1.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause hospitalisation (all occurrences) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.75, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Ventricular dysfunction (as defined by trialists) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change in NP level at the end of follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Natriuretic peptide‐guided treatment versus standard care</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013015.pub2/references#CD013015-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013015.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013015-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013015-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD013015-note-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD013015-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013015-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013015-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013015\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013015\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013015\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013015\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013015\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QzbxnhyM&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013015.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013015.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013015.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013015.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013015.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717844464"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013015.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717844468"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013015.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc1d58dc69377',t:'MTc0MDcxNzg0NC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 